CUMULATIVE
SUPPLEMENT 7
JULY 2000



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

20TH EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF INFORMATION TECHNOLOGY
DIVISION OF DATA MANAGEMENT AND SERVICES

2000

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

20TH EDITION

Cumulative Supplement 7

July 2000

CONTENTS

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

20TH EDITION

CUMULATIVE SUPPLEMENT 7
JULY 2000

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 20th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Patent and Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the patent and/or exclusivity expires. Refer to the Patent and Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Information regarding drug patents and exclusivity for an approved product will appear in this addendum as it is received and may not correspond with the month the drug product is approved and published in the Rx/OTC sections of the Cumulative Supplement.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

New additions to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol **>ADD>** to the left of the line on which new information exists. The **>ADD>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>DLT>** (DELETE) to the left of the line. The **>DLT>** symbol is dropped in subsequent Cumulative Supplements for that item. The shaded print remains in the Prescription Drug Product List and OTC Drug Product Lists in all Cumulative Supplements (hard copy only) for this edition.

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 20h Edition List will then be added to the "Discontinued Drug Product List" appearing in the 21st Edition.

1.2 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When

this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
GALDERMA LABS INC (GALDERMA)	GALDERMA LABORATORIES LP (GALDERMA LABS LP)
GLOBAL PHARMACEUTICAL CORP (GLOBAL PHARM)	IMPAX LABORATORIES INC (IMPAX LABS)
HOECHST MARION ROUSSEL INC (HOECHST MARION RSSL)	AVENTIS PHARMACEUTICALS INC (AVENTIS PHARMS)
RHONE POULENC RORER PHARMACEUTICALS INC (RHONE POULENCE RORER)	AVENTIS PHARMACEUTICALS PRODUCTS INC (AVENTIS PHARM PROD)
TAP HOLDINGS INC (TAP HOLDINGS)	TAP PHARMACEUTICAL PRODUCTS INC (TAP PHARM)
ZENECA INC (ZENECA)	ASTRAZENECA PHARMACEUTICALS LP (ASTRAZENECA PHARMS)
ZENECA LTD (ZENECA)	ASTRAZENECA UK LTD (ASTRAZENECA UK)
ZENECA PHARMACEUTICALS DIV ZENECA INC (ZENECA)	ASTRAZENECA PHARMACEUTICALS LP (ASTRAZENECA PHARMS)

1.3 DICLOFENAC SODIUM OPHTHALMIC SOLUTION 0.1%

Two NDAs have been approved for diclofenac sodium ophthalmic solution 0.1% (DSOS), (1) Ciba's NDA 20-037 for Voltaren and (2) Falcon Pharms' (Alcon) NDA 20-809 for DSOS. Alcon was required to do a study comparing their DSOS to Voltaren and to a placebo control in post cataract surgical inflammation. This study was necessary to demonstrate that the different formulation of the Alcon drug product did not affect the safety and/or effectiveness of the proposed drug product for this indication. Prior to the approval of Alcon's DSOS Ciba did clinical studies and was approved for two additional indications for the temporary relief of pain and photophobia in patients undergoing corneal refractive surgery. Three years of Waxman-Hatch marketing exclusivity was granted to Ciba for these two new uses.

Since the treatment of pain has a different site of action than the anti-inflammatory or photophobia indications the Agency did not have information to support a recommendation that the Alcon and Ciba DSOS are therapeutically equivalent for the treatment of pain. The designation of therapeutic equivalence at this time applies only to the anti-inflammatory indication. The therapeutic equivalence designation will apply to the photophobia indication upon expiration of Ciba's marketing exclusivity.

1.4 AVAILABILITY OF THE EDITION

The 20th Edition of the Orange Book and its monthly cumulative supplements are available by subscription from the Government Printing Office:

Superintendent of Documents
Government Printing Office
P.O. Box 371954
Pittsburgh, PA 15250-7954

The telephone number to charge your subscription is 202-512-1800. The cost is $90.00 annually.

The Approved Drug Products with Therapeutic Equivalence Evaluation (Orange Book) and related drug information is also available on the Internet at the Food and Drug Administration, Center for Drug Evaluation and Research, Drug Info page.

There is an Electronic Orange Book Query (EOB) at http://www.fda.gov/cder/ob. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder or applicant number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product. The data is updated concurrently with the publication of the annual edition or monthly cumulative supplements.

The Internet version of the hard copy Orange Book annual edition is at
http://www.fda.gov/cder/orange/adp.htm.

The Internet version of the hard copy monthly supplement is at
http://www.fda.gov/cder/orange/supplement/cspreface.htm. Changes to the annual edition are listed separately by month.

There are ASCII text files of the Orange Book drug product data at
http://www.fda.gov/cder/orange/obreadme.htm. The drug product text files are zipped into zipobtxt.exe. The files are updated concurrently with the publication of the annual edition or monthly cumulative supplements. Appendix A and Appendix B are updated quarterly.

The 20th annual edition of the 1999 Orange Book Patent and Exclusivity List is at
http://www.fda.gov/cder/orange/20bookpub.pdf.

The current year Patent and Exclusivity cumulative supplement list that denotes the current month additions is at
http://www.fda.gov/cder/orange/supplement/patents.pdf.

The Drug Price Competition and Patent Term Restoration Act requires that patent information be filed with all newly submitted Section 505 drug applications. To facilitate industry submission of the information, a patent submission sample format is available in HTML and PDF format at:
http://www.fda.gov/cder/orange/patdecl.pdf
http://www.fda.gov/cder/orange/patdecl.html

The current listing of the Orphan Product Designations and Approvals is available at
http://www.fda.gov/orphan/designat/list.htm.

1.5 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 1999) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 1999	MAR 2000	JUN 2000	SEP 2000
DRUG PRODUCTS LISTED	10045	10082	10186	
SINGLE SOURCE	2599 (25.9%)	2596 (25.7%)	2617 (25.7%)	
MULTISOURCE	7335 (73.0%)	7375 (73.2%)	7458 (73.2%)	
THERAPEUTICALLY EQUIVALENT	6986 (69.5%)	7040 (69.8%)	7132 (70.0%)	
NOT THERAPEUTICALLY EQUIVALENT	349 (3.5%)	335 (3.3%)	326 (3.2%)	
EXCEPTIONS[1]	111 (1.1%)	111 (1.1%)	111 (1.1%)	
NEW MOLECULAR ENTITIES APPROVED	0	6	11	
NUMBER OF APPLICANTS	576	575	580	

[1]Amino acid-containing products of varying composition (see Introduction, page xx of the List).

ACETAMINOPHEN; BUTALBITAL

CAPSULE; ORAL
PHRENILIN FORTE

AB	+	AMARIN PHARMS	650MG;50MG	N88831 001 JUN 19, 1985
AB	*	CARNRICK	650MG;50MG	N88831 001 JUN 19, 1985

TABLET; ORAL
PHRENILIN

AB	+	AMARIN PHARMS	325MG;50MG	N87811 001 JUN 19, 1985
AB	*	CARNRICK	325MG;50MG	N87811 001 JUN 19, 1985

ACETAMINOPHEN; CODEINE PHOSPHATE

SUSPENSION; ORAL
ACETAMINOPHEN AND CODEINE PHOSPHATE

AA	AMARIN PHARMS	120MG/5ML;12MG/5ML	N86024 001
AA	CARNRICK	120MG/5ML;12MG/5ML	N86024 001

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN

> ADD >	AA	BARR	500MG;2.5MG	N40307 001 JUL 26, 2000
> ADD >	AA		500MG;5MG	N40308 001 JUL 26, 2000
> ADD >	AA		500MG;7.5MG	N40307 002 JUL 26, 2000
> ADD >	AA		500MG;10MG	N40309 001 JUL 26, 2000
> ADD >	AA		650MG;7.5MG	N40307 003 JUL 26, 2000
> ADD >	AA		650MG;10MG	N40307 004 JUL 26, 2000
> ADD >	AA		750MG;7.5MG	N40308 002 JUL 26, 2000
> ADD >	AA	MALLINCKRODT	325MG;10MG	N40400 001 JUL 26, 2000
> ADD >	AA	UCB	325MG;10MG	N40248 002 APR 28, 2000
	+		325MG;7.5MG	N40248 001 APR 28, 2000

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA		VINTAGE PHARMS	325MG;10MG	N40355 001 MAY 31, 2000
AA			500MG;10MG	N40356 001 MAY 31, 2000
AA			660MG;10MG	N40358 001 MAY 31, 2000
		LORTAB UCB	325MG;5MG	N40099 001 JUN 25, 1997
	@		325MG;5MG	N40099 001 JUN 25, 1997
		NORCO		
AA	+	WATSON LABS	325MG;10MG	N40148 001 FEB 14, 1997
	*		325MG;10MG	N40148 001 FEB 14, 1997

ACETAMINOPHEN; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL
PENTAZOCINE HCL AND ACETAMINOPHEN

AB		WATSON LABS	650MG;EQ 25MG BASE	N74699 001 MAR 24, 2000
		TALACEN		
AB	+	SANOFI SYNTHELABO	650MG;EQ 25MG BASE	N18458 001 SEP 23, 1982
	*		650MG;EQ 25MG BASE	N18458 001 SEP 23, 1982

ACETOHEXAMIDE

TABLET; ORAL
ACETOHEXAMIDE

AB		BARR	500MG	N70870 001 FEB 09, 1987
AB	+		500MG	N70870 001 FEB 09, 1987
		DYMELOR		
AB		LILLY	250MG	N13378 002
AB	*		500MG	N13378 001
	@		250MG	N13378 002
	@		500MG	N13378 001

ADAPALENE

CREAM; TOPICAL
DIFFERIN
+ GALDERMA LABS LP 0.1% N20748 001 MAY 26, 2000

ALBUMIN HUMAN

INJECTABLE; INJECTION
OPTISON
> ADD > + MALLINCKRODT 10MG/ML N20899 001 DEC 31, 1997
> ADD > * MOLECULAR BIOSYSTEMS 10MG/ML N20899 001 DEC 31, 1997
> DLT >
> DLT >

ALBUTEROL

AEROSOL, METERED; INHALATION
ALBUTEROL
AB MEDISOL 0.09MG/INH N74072 001 AUG 01, 1996
AB SIDMAK LABS CA 0.09MG/INH N74072 001 AUG 01, 1996

ALBUTEROL SULFATE

SOLUTION; INHALATION
ALBUTEROL SULFATE
AN BAUSCH AND LOMB EQ 0.083% BASE N75358 001 MAR 29, 2000

ALOSETRON HYDROCHLORIDE

TABLET; ORAL
LOTRONEX
+ GLAXO WELLCOME EQ 1MG BASE N21107 001 FEB 09, 2000

ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE

INJECTABLE; INJECTION
MULTI-12
+ SABEX 2 IU/ML;20MG/ML;12 UGM/ML;40 IU/ML; 1 UGM/ML;3MG/ML;80 UGM/ML;8MG/ML; 0.8MG/ML;0.72MG/ML;0.6MG/ML; 600 IU/ML N21163 001 MAY 18, 2000

ALTRETAMINE

CAPSULE; ORAL
HEXALEN
+ MEDIMMUNE ONCOLOGY 50MG N19926 001 DEC 26, 1990
* US BIOSCIENCE 50MG N19926 001 DEC 26, 1990

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL
AMANTADINE HCL
AB GENEVA PHARMS TECH 100MG N71293 001 FEB 18, 1987
AB INVAMED 100MG N71293 001 FEB 18, 1987

AMIFOSTINE

INJECTABLE; INJECTION
ETHYOL
+ MEDIMMUNE ONCOLOGY 500MG/VIAL N20221 001 DEC 08, 1995
* US BIOSCIENCE 500MG/VIAL N20221 001 DEC 08, 1995

AMINO ACIDS

INJECTABLE; INJECTION
> DLT > NOVAMINE 15% SULFITE FREE IN PLASTIC CONTAINER
> DLT > BAXTER HLTHCARE 15% N20107 001 FEB 05, 1993
> DLT >

AMINO ACIDS

INJECTABLE; INJECTION
NOVAMINE 15% SULFITE FREE IN PLASTIC CONTAINER

>ADD>	@ BAXTER HLTHCARE	15%	N20107 001 FEB 05, 1993	>DLT>
>ADD>				>DLT>
>ADD>				>DLT>
	TROPHAMINE			>DLT>
	B BRAUN	6%	N19018 001 JUL 20, 1984	>ADD>
	+	6%	N19018 001 JUL 20, 1984	>ADD>
				>ADD>
				>ADD>
	TROPHAMINE 10%			
	B BRAUN	10%	N19018 003 SEP 07, 1988	
	+	10%	N19018 003 SEP 07, 1988	

AMINOPHYLLINE

TABLET; ORAL

	AMINOPHYLLINE		
AB	GLOBAL PHARM	100MG	N84574 001
AB		200MG	N84576 001
	@ IMPAX LABS	100MG	N84574 001
	@	200MG	N84576 001

AMIODARONE HYDROCHLORIDE

TABLET; ORAL

	AMIODARONE HCL		
	+ EON	400MG	N75315 002 JUN 30, 2000

AMRINONE LACTATE

INJECTABLE; INJECTION

	AMRINONE		
AP	BEDFORD	EQ 5MG BASE/ML	N75513 001 MAY 09, 2000
	AMRINONE LACTATE		
AP	BAXTER PHARM PROD	EQ 5MG BASE/ML	N75542 001 MAY 10, 2000

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL

	AGRYLIN		
	ROBERTS LABS	EQ 0.5MG BASE	N20333 001 MAR 14, 1997
	*	EQ 1MG BASE	N20333 002 MAR 14, 1997
	SHIRE LABS	EQ 0.5MG BASE	N20333 001 MAR 14, 1997
	+	EQ 1MG BASE	N20333 002 MAR 14, 1997

ARDEPARIN SODIUM

INJECTABLE; INJECTION

	NORMIFLO		
	+ PHARMACIA AND UPJOHN	5,000 UNITS/0.5ML	N20227 002 MAY 23, 1997
	+	10,000 UNITS/0.5ML	N20227 001 MAY 23, 1997
	* WYETH AYERST	5,000 UNITS/0.5ML	N20227 002 MAY 23, 1997
	*	10,000 UNITS/0.5ML	N20227 001 MAY 23, 1997

ARGATROBAN

INJECTABLE; INJECTION

	ACOVA		
	+ TX BIOTECH	100MG/ML	N20883 001 JUN 30, 2000

ARTICAINE HYDROCHLORIDE; EPINEPHRINE

INJECTABLE; INJECTION

	SEPTOCAINE		
	+ DEPROCO	4%;EQ 0.01MG BASE/ML	N20971 001 APR 03, 2000

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PHYTONADIONE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A PALMITATE; VITAMIN E

INJECTABLE; INJECTION
KABIVITE PED P + W KIT
+ FRESENIUS KABI — N/A,80MG/VIAL;N/A,0.02MG/VIAL;N/A, 0.001MG/VIAL;400 IU/10ML,N/A;N/A, 0.14MG/VIAL;N/A,17MG/VIAL;N/A, 5MG/VIAL;0.2MG/10ML,N/A;N/A, 1MG/VIAL;N/A,1.4MG/VIAL;N/A, 1.2MG/VIAL;EQ 2,300 UNITS BASE/10ML, N/A;7 IU/10ML,N/A — N20176 001 DEC 29, 1993

VITAPED
@ FRESENIUS KABI — N/A,80MG/VIAL;N/A,0.02MG/VIAL;N/A, 0.001MG/VIAL;400 IU/10ML,N/A;N/A, 0.14MG/VIAL;N/A,17MG/VIAL;N/A, 5MG/VIAL;0.2MG/10ML,N/A;N/A, 1MG/VIAL;N/A,1.4MG/VIAL;N/A, 1.2MG/VIAL;EQ 2,300 UNITS BASE/10ML, N/A;7 IU/10ML,N/A — N20176 001 DEC 29, 1993

> ADD > ATOVAQUONE; PROGUANIL HYDROCHLORIDE

> ADD > TABLET; ORAL
> ADD > MALARONE
> ADD > + GLAXO WELLCOME — 250MG;100MG — N21078 001 JUL 14, 2000
> ADD > MALARONE PEDIATRIC
> ADD > + GLAXO WELLCOME — 62.5MG;25MG — N21078 002 JUL 14, 2000

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET; ORAL
MOTOFEN
> ADD > + AMARIN PHARMS — 0.025MG;1MG — N17744 002
> DLT > * CARNRICK — 0.025MG;1MG — N17744 002
MOTOFEN HALF-STRENGTH
> ADD > @ AMARIN PHARMS — 0.025MG;0.5MG — N17744 001
> DLT > @ CARNRICK — 0.025MG;0.5MG — N17744 001

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL
DIPHENOXYLATE HCL AND ATROPINE SULFATE
AA PAR PHARM — 0.025MG;2.5MG — N40357 001 MAY 02, 2000

ATROPINE SULFATE; EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION
ENLON-PLUS
+ BAXTER PHARM PROD — 0.14MG/ML;10MG/ML — N19677 001 NOV 06, 1991
+ — 0.14MG/ML;10MG/ML — N19678 001 NOV 06, 1991
* OHMEDA — 0.14MG/ML;10MG/ML — N19677 001 NOV 06, 1991
* — 0.14MG/ML;10MG/ML — N19678 001 NOV 06, 1991

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
OPTIVAR
+ ASTA — 0.05% — N21127 001 MAY 22, 2000

> ADD > BALSALAZIDE DISODIUM

> ADD > CAPSULE; ORAL
> ADD > COLAZAL
> ADD > + SALIX — 750MG — N20610 001 JUL 18, 2000

BENZTROPINE MESYLATE

TABLET; ORAL
BENZTROPINE MESYLATE
AA GENEVA PHARMS TECH — 0.5MG — N72264 001 FEB 27, 1989
AA — 1MG — N72265 001 FEB 27, 1989
AA — 2MG — N72266 001 FEB 27, 1989

BENZTROPINE MESYLATE

TABLET; ORAL

	BENZTROPINE MESYLATE			
AA	INVAMED	0.5MG	N72264 001	FEB 27, 1989
AA		1MG	N72265 001	FEB 27, 1989
AA		2MG	N72266 001	FEB 27, 1989

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

	BETAXOLOL			
AT	AKORN	EQ 0.5% BASE	N75386 001	JUN 30, 2000
	BETOPTIC			
AT	+ ALCON	EQ 0.5% BASE	N19270 001	AUG 30, 1985
	+	EQ 0.5% BASE	N19270 001	AUG 30, 1985

BETHANECHOL CHLORIDE

INJECTABLE; INJECTION

	URECHOLINE			
	+ MERCK	5MG/ML	N06536 001	
	@	5MG/ML	N06536 001	

TABLET; ORAL

	BETHANECHOL CHLORIDE			
AA	DANBURY PHARMA	10MG	N84408 001	
AA		25MG	N84441 001	
AA		50MG	N87444 001	
	@	10MG	N84408 001	
	@	25MG	N84441 001	
	@	50MG	N87444 001	
	DUVOID			
AA	ROBERTS LABS	10MG	N86262 001	
AA		25MG	N86263 001	
AA		50MG	N85882 003	
	@	10MG	N86262 001	
	@	25MG	N86263 001	
	@	50MG	N85882 003	
	MYOTONACHOL			
AA	GLENWOOD	5MG	N84188 001	

BETHANECHOL CHLORIDE

TABLET; ORAL

	MYOTONACHOL			
AA	GLENWOOD	10MG	N84188 003	
AA		25MG	N84188 004	
	@	5MG	N84188 001	
	@	10MG	N84188 003	
	@	25MG	N84188 004	
	URECHOLINE			
AA	+ MERCK	5MG	N06536 003	
AA	+	10MG	N06536 002	
AA	+	25MG	N06536 004	
AA	+	50MG	N06536 005	
	@	5MG	N06536 003	
	@	10MG	N06536 002	
	@	25MG	N06536 004	
	@	50MG	N06536 005	
	+ ODYSSEY PHARMS	5MG	N89095 001	DEC 19, 1985
	+	10MG	N88440 001	MAY 29, 1984
	+	25MG	N88441 001	MAY 29, 1984
	+	50MG	N89096 001	DEC 19, 1985
AA	+ SIDMAK LABS NJ	5MG	N89095 001	DEC 19, 1985
AA	+	10MG	N88440 001	MAY 29, 1984
AA	+	25MG	N88441 001	MAY 29, 1984
AA	+	50MG	N89096 001	DEC 19, 1985

BEXAROTENE

GEL; TOPICAL

	TARGRETIN			
	+ LIGAND	1%	N21056 001	JUN 28, 2000

BLEOMYCIN SULFATE

INJECTABLE; INJECTION

	BLEOMYCIN			
AP	FAULDING	EQ 15 UNITS BASE/VIAL	N65031 001	MAR 10, 2000

BLEOMYCIN SULFATE

INJECTABLE; INJECTION
BLEOMYCIN

AP	FAULDING	EQ 30 UNITS BASE	N65031 002 MAR 10, 2000	
AP	GENSIA SICOR PHARMS	EQ 15 UNITS BASE/VIAL	N65033 001 JUN 27, 2000	
AP		EQ 30 UNITS BASE/VIAL	N65033 002 JUN 27, 2000	

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION
BRETYLIUM TOSYLATE

AP	ASTRAZENECA	50MG/ML	N71151 001 AUG 10, 1987	
	@	50MG/ML	N71151 001 AUG 10, 1987	

BROMPHENIRAMINE MALEATE; CODEINE PHOSPHATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

SYRUP; ORAL
DIMETANE-DC

> DLT >	AA	+	ROBINS AH	2MG/5ML;10MG/5ML; 12.5MG/5ML	N11694 006 MAR 29, 1984
> DLT >		@		2MG/5ML;10MG/5ML; 12.5MG/5ML	N11694 006 MAR 29, 1984

MYPHETANE DC

> DLT >	AA		MORTON GROVE	2MG/5ML;10MG/5ML; 12.5MG/5ML	N88904 001 FEB 21, 1985
> ADD >	AA	+		2MG/5ML;10MG/5ML; 12.5MG/5ML	N88904 001 FEB 21, 1985

BUPROPION HYDROCHLORIDE

TABLET; ORAL
BUPROPION HCL

AB	INVAMED	75MG	N75584 001 FEB 07, 2000	

BUPROPION HYDROCHLORIDE

TABLET; ORAL
BUPROPION HCL

AB	INVAMED	100MG	N75584 002 FEB 07, 2000	
AB	MYLAN	75MG	N75491 001 APR 17, 2000	
AB		100MG	N75491 002 APR 17, 2000	

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL
BUSPAR

	+	BRISTOL MYERS SQUIBB	15MG	N18731 003 APR 22, 1996
	@		30MG	N18731 004 APR 22, 1996
			15MG	N18731 003 APR 22, 1996
	+		30MG	N18731 004 APR 22, 1996

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION
BUTORPHANOL TARTRATE

AP	ABBOTT	1MG/ML	N75559 001 MAR 20, 2000	
AP		2MG/ML	N75559 002 MAR 20, 2000	

CALCIUM CHLORIDE

INJECTABLE; INJECTION
CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER

	+	ABBOTT	100MG/ML	N21117 001 JAN 28, 2000

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SOLUTION; PERFUSION, CARDIAC

CARDIOPLEGIC IN PLASTIC CONTAINER

AT	BAXTER HLTHCARE	17.6MG/100ML;325.3MG/100ML; 119.3MG/100ML;643MG/100ML	N75323 001	APR 21, 2000

PLEGISOL IN PLASTIC CONTAINER

AT	+ ABBOTT	17.6MG/100ML;325.3MG/100ML; 119.3MG/100ML;643MG/100ML	N18608 001	FEB 26, 1982
	*	17.6MG/100ML;325.3MG/100ML; 119.3MG/100ML;643MG/100ML	N18608 001	FEB 26, 1982

CANDICIDIN

OINTMENT; VAGINAL

VANOBID

	@ AVENTIS PHARMS	0.6MG/GM	N61596 001
	* HOECHST MARION RSSL	0.6MG/GM	N61596 001

TABLET; VAGINAL

VANOBID

	@ AVENTIS PHARMS	3MG	N61613 001	> ADD >
	* HOECHST MARION RSSL	3MG	N61613 001	> ADD >
				> ADD >
				> ADD >
				> ADD >

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CAPTOPRIL AND HYDROCHLOROTHIAZIDE

> DLT >	AB	DANBURY PHARMA	50MG;25MG	N74832 001	> DLT >
> DLT >				DEC 29, 1997	> ADD >
> ADD >		@	50MG;25MG	N74832 001	
> ADD >				DEC 29, 1997	

CARBIDOPA; LEVODOPA

TABLET, EXTENDED RELEASE; ORAL

CARBIDOPA AND LEVODOPA

AB	MYLAN	25MG;100MG	N75091 002	APR 21, 2000

SINEMET CR

AB	DUPONT PHARMS	25MG;100MG	N19856 002	DEC 24, 1992

CARBIDOPA; LEVODOPA

TABLET, EXTENDED RELEASE; ORAL

SINEMET CR

	DUPONT PHARMS	25MG;100MG	N19856 002	DEC 24, 1992

CARTEOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CARTEOLOL HCL

AT	ALCON	1%	N75476 001	JAN 03, 2000
AT	BAUSCH AND LOMB	1%	N75546 001	JAN 20, 2000

OCUPRESS

AT	+ CIBA	1%	N19972 001	MAY 23, 1990
	*	1%	N19972 001	MAY 23, 1990

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN AND DEXTROSE

	+ B BRAUN	EQ 500MG BASE/VIAL	N50779 001	JUL 27, 2000
	+	EQ 1GM BASE/VIAL	N50779 002	JUL 27, 2000

CEFAZOLIN SODIUM

AP	AM PHARM PARTNERS	EQ 1MG BASE/VIAL	N64169 002	AUG 14, 1998
AP		EQ 1GM BASE/VIAL	N64169 002	AUG 14, 1998

CEFDINIR

CAPSULE; ORAL

OMNICEF

	+ ABBOTT	300MG	N50739 001	DEC 04, 1997
	* PARKE DAVIS	300MG	N50739 001	DEC 04, 1997

POWDER FOR RECONSTITUTION; ORAL

OMNICEF

	+ ABBOTT	125MG/5ML	N50749 001	DEC 04, 1997

CEFDINIR

POWDER FOR RECONSTITUTION; ORAL
OMNICEF

*	PARKE DAVIS	125MG/5ML	N50749 001	
			DEC 04, 1997	

CEFOTAXIME SODIUM

INJECTABLE; INJECTION
CEFOTAXIME

AP	AM PHARM PARTNERS	EQ 500MG BASE/VIAL	N64200 001	
			MAR 24, 2000	
AP		EQ 1GM BASE/VIAL	N64200 002	
			MAR 24, 2000	
AP		EQ 2GM BASE/VIAL	N64200 003	
			MAR 24, 2000	
AP		EQ 10GM BASE/VIAL	N64201 001	
			MAR 24, 2000	
+		EQ 20GM BASE/VIAL	N64201 002	
			MAR 24, 2000	

CLAFORAN

AP	+ AVENTIS PHARMS	EQ 500MG BASE/VIAL	N50547 001	
AP	+	EQ 1GM BASE/VIAL	N50547 002	
AP	+	EQ 2GM BASE/VIAL	N50547 003	
AP	+	EQ 10GM BASE/VIAL	N50547 004	
			DEC 29, 1983	
+	HOECHST MARION RSSL	EQ 500MG BASE/VIAL	N50547 001	
+		EQ 1GM BASE/VIAL	N50547 002	
+		EQ 2GM BASE/VIAL	N50547 003	
+		EQ 10GM BASE/VIAL	N50547 004	
			DEC 29, 1983	

CEFOXITIN SODIUM

INJECTABLE; INJECTION
CEFOXITIN

> ADD >				
> ADD >	AP	AM PHARM PARTNERS	EQ 1GM BASE/VIAL	N65012 001
> ADD >				JUL 03, 2000
> ADD >	AP		EQ 2GM BASE/2VIAL	N65012 002
> ADD >				JUL 03, 2000
> ADD >	AP		EQ 10GM BASE/VIAL	N65011 001
> ADD >				JUL 03, 2000

MEFOXIN

> ADD >	AP	+ MERCK	EQ 1GM BASE/VIAL	N50517 001
> ADD >	AP		EQ 1GM BASE/VIAL	N62757 001
> ADD >				JAN 08, 1987
> ADD >	AP	+	EQ 10GM BASE/VIAL	N50517 003
> DLT >		*	EQ 1GM BASE/VIAL	N50517 001
> DLT >			EQ 1GM BASE/VIAL	N62757 001
> DLT >				JAN 08, 1987
> DLT >		*	EQ 2GM BASE/VIAL	N50517 002
> DLT >			EQ 2GM BASE/VIAL	N62757 002
> DLT >				JAN 08, 1987
> DLT >		*	EQ 10GM BASE/VIAL	N50517 003

CEFOXITIN SODIUM

INJECTABLE; INJECTION
MEFOXIN

> ADD >	AP	+ MERCK	EQ 2GM BASE/VIAL	N50517 002
> ADD >	AP		EQ 2GM BASE/VIAL	N62757 002
> ADD >				JAN 08, 1987
> ADD >	AP	+	EQ 10GM BASE/VIAL	N50517 003
> DLT >		*	EQ 1GM BASE/VIAL	N50517 001
> DLT >			EQ 1GM BASE/VIAL	N62757 001
> DLT >				JAN 08, 1987
> DLT >		*	EQ 2GM BASE/VIAL	N50517 002
> DLT >			EQ 2GM BASE/VIAL	N62757 002
> DLT >				JAN 08, 1987
> DLT >		*	EQ 10GM BASE/VIAL	N50517 003

CEFTIBUTEN DIHYDRATE

CAPSULE; ORAL
CEDAX

+	DJ PHARMA	EQ 400MG BASE	N50685 002	
			DEC 20, 1995	
*	SCHERING PLOUGH	EQ 400MG BASE	N50685 002	
			DEC 20, 1995	

POWDER FOR RECONSTITUTION; ORAL
CEDAX

	DJ PHARMA	EQ 90MG BASE/5ML	N50686 001	
			DEC 20, 1995	
+		EQ 180MG BASE/5ML	N50686 002	
			DEC 20, 1995	
*	SCHERING PLOUGH	EQ 90MG BASE/5ML	N50686 001	
			DEC 20, 1995	
*		EQ 180MG BASE/5ML	N50686 002	
			DEC 20, 1995	

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION
ROCEPHIN

+	HLR	EQ 250MG BASE/VIAL	N50585 001
			DEC 21, 1984
+		EQ 500MG BASE/VIAL	N50585 002
			DEC 21, 1984
+		EQ 1GM BASE/VIAL	N50585 003
			DEC 21, 1984

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION
ROCEPHIN

+	HLR	EQ 2GM BASE/VIAL	N50585 004 DEC 21, 1984	
+		EQ 10GM BASE/VIAL	N50585 005 DEC 21, 1984	
*	ROCHE	EQ 250MG BASE/VIAL	N50585 001 DEC 21, 1984	
*		EQ 500MG BASE/VIAL	N50585 002 DEC 21, 1984	
*		EQ 1GM BASE/VIAL	N50585 003 DEC 21, 1984	
*		EQ 2GM BASE/VIAL	N50585 004 DEC 21, 1984	
*		EQ 10GM BASE/VIAL	N50585 005 DEC 21, 1984	> DLT >

ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER

@	HLR	EQ 10MG BASE/ML	N50624 001 FEB 11, 1987	> DLT >
+		EQ 20MG BASE/ML	N50624 002 FEB 11, 1987	> ADD >
+		EQ 40MG BASE/ML	N50624 003 FEB 11, 1987	> ADD >
@	ROCHE	EQ 10MG BASE/ML	N50624 001 FEB 11, 1987	> ADD >
*		EQ 20MG BASE/ML	N50624 002 FEB 11, 1987	> ADD >
*		EQ 40MG BASE/ML	N50624 003 FEB 11, 1987	> ADD >

CEFTRIAXONE SODIUM; LIDOCAINE

INJECTABLE; INJECTION
ROCEPHIN KIT

+	HLR	EQ 1GM BASE/VIAL,N/A;N/A, 1%	N50585 006 MAY 08, 1996
+		EQ 500MG BASE/VIAL,N/A;N/A, 1%	N50585 007 MAY 08, 1996
*	ROCHE	EQ 1GM BASE/VIAL,N/A;N/A, 1%	N50585 006 MAY 08, 1996
*		EQ 500MG BASE/VIAL,N/A;N/A, 1%	N50585 007 MAY 08, 1996

CEPHALEXIN

POWDER FOR RECONSTITUTION; ORAL
KEFLEX

AB	* LILLY	EQ 125MG BASE/5ML	N50406 001	
AB	*	EQ 250MG BASE/5ML	N50406 002	
AB		EQ 250MG BASE/5ML	N62117 003	
AB	+	EQ 250MG BASE/5ML	N62117 003	
	@	EQ 125MG BASE/5ML	N50406 001	
	@	EQ 250MG BASE/5ML	N50406 002	

CERIVASTATIN SODIUM

TABLET; ORAL
BAYCOL

*	BAYER	0.4MG	N20740 005 MAY 24, 1999	
		0.4MG	N20740 005 MAY 24, 1999	
+		0.8MG	N20740 006 JUL 24, 2000	

CEVIMELINE HYDROCHLORIDE

CAPSULE; ORAL
EVOXAC

+	SNOWBRAND	EQ 30MG BASE	N20989 002 JAN 11, 2000

CHENODIOL

TABLET; ORAL
CHENIX

@	AXCAN	250MG	N18513 002 JUL 28, 1983
	@ AXCAN SCANDIPHARM	250MG	N18513 002 JUL 28, 1983

CHLORPHENIRAMINE MALEATE

TABLET; ORAL
CHLORPHENIRAMINE MALEATE

AA	GLOBAL PHARM	4MG	N80809 001
	@ IMPAX LABS	4MG	N80809 001

CICLOPIROX

CREAM; TOPICAL
LOPROX
\+ AVENTIS PHARMS 0.77% N18748 001 DEC 30, 1982

LOTION; TOPICAL
LOPROX
\+ AVENTIS PHARMS 0.77% N19824 001 DEC 30, 1988

CICLOPIROX OLAMINE

CREAM; TOPICAL
LOPROX
* HOECHST MARION RSSL 1% N18748 001 DEC 30, 1982

LOTION; TOPICAL
LOPROX
* HOECHST MARION RSSL 1% N19824 001 DEC 30, 1988

CIMETIDINE HYDROCHLORIDE

SOLUTION; ORAL
CIMETIDINE HCL
AA NOVEX EQ 300MG BASE/5ML N75560 001 MAR 15, 2000

CISAPRIDE MONOHYDRATE

SUSPENSION; ORAL
PROPULSID
* JANSSEN EQ 1MG BASE/ML N20398 001 SEP 15, 1995
@ EQ 1MG BASE/ML N20398 001 SEP 15, 1995

TABLET; ORAL
PROPULSID
JANSSEN
* EQ 10MG BASE N20210 001 JUL 29, 1993
EQ 20MG BASE N20210 002 DEC 23, 1993

CISAPRIDE MONOHYDRATE

TABLET; ORAL
PROPULSID
@ JANSSEN EQ 10MG BASE N20210 001 JUL 29, 1993
@ EQ 20MG BASE N20210 002 DEC 23, 1993

CISPLATIN

INJECTABLE; INJECTION
CISPLATIN
AP GENSIA SICOR PHARMS 1MG/ML N74814 001 MAY 16, 2000
AP PHARMACHEMIE 1MG/ML N74656 001 MAY 16, 2000

CITALOPRAM HYDROBROMIDE

TABLET; ORAL
CELEXA
FOREST LABS EQ 40MG BASE N20822 003 JUL 17, 1998
* EQ 60MG BASE N20822 004 JUL 17, 1998
\+ EQ 40MG BASE N20822 003 JUL 17, 1998
@ EQ 60MG BASE N20822 004 JUL 17, 1998

CLADRIBINE

INJECTABLE; INJECTION
CLADRIBINE
AP BEDFORD 1MG/ML N75405 001 FEB 28, 2000

CLARITHROMYCIN

TABLET; ORAL
BIAXIN
ABBOTT 250MG N50662 001 OCT 31, 1991

CLARITHROMYCIN

TABLET; ORAL
BIAXIN

+	ABBOTT	250MG	N50662 001 OCT 31, 1991	

TABLET, EXTENDED RELEASE; ORAL
BIAXIN XL

+	ABBOTT	500MG	N50775 001 MAR 03, 2000	

CLINDAMYCIN PHOSPHATE

GEL; TOPICAL
CLEOCIN T

AB	+ PHARMACIA AND UPJOHN	EQ 1% BASE	N50615 001 JAN 07, 1987	> DLT >
	#	EQ 1% BASE	N50615 001 JAN 07, 1987	> ADD >

CLINDAMYCIN PHOSPHATE

AB	ALTANA	EQ 1% BASE	N64160 001 JAN 28, 2000	> DLT > > ADD >

SOLUTION; TOPICAL
CLINDAMYCIN PHOSPHATE

AT	CLAY PARK	EQ 1% BASE	N65049 001 MAY 25, 2000	> DLT > > ADD >

CLOBETASOL PROPIONATE

AEROSOL; TOPICAL
OLUX FOAM

+	CONNETICS	0.05%	N21142 001 MAY 26, 2000	> DLT > > ADD >

CREAM; TOPICAL
CLOBETASOL PROPIONATE

AB2	TARO	0.05%	N75633 001 MAY 17, 2000	

GEL; TOPICAL
CLOBETASOL PROPIONATE

AB	ALTANA	0.05%	N75368 001 FEB 15, 2000	

CLORAZEPATE DIPOTASSIUM

TABLET; ORAL
CLORAZEPATE DIPOTASSIUM

AB	TARO	3.75MG	N75731 003 APR 27, 2000
AB		7.5MG	N75731 002 APR 27, 2000
AB		15MG	N75731 001 APR 27, 2000

CLOXACILLIN SODIUM

CAPSULE; ORAL
CLOXACILLIN SODIUM

AB	+ APOTHECON	EQ 250MG BASE	N61452 001	> DLT >
AB	+	EQ 500MG BASE	N61452 002	> DLT >
	@	EQ 250MG BASE	N61452 001	> ADD >
	@	EQ 500MG BASE	N61452 002	> ADD >

CLOXAPEN

AB	SMITHKLINE BEECHAM	EQ 500MG BASE	N61806 002	> DLT >
AB	+	EQ 500MG BASE	N61806 002	> ADD >

COLESEVELAM HYDROCHLORIDE

CAPSULE; ORAL
WELCHOL

#	GELTEX	375MG	N21141 001 MAY 26, 2000	> DLT > > ADD >
+	SANKYO PHARMA INC	375MG	N21141 001 MAY 26, 2000	> DLT > > ADD >

TABLET; ORAL
WELCHOL

#	GELTEX	625MG	N21176 001 MAY 26, 2000	> DLT > > ADD >
+	SANKYO PHARMA INC	625MG	N21176 001 MAY 26, 2000	> DLT > > ADD >

CORTISONE ACETATE

TABLET; ORAL
CORTISONE ACETATE

BP	GLOBAL PHARM	25MG	N09458 001
	@ IMPAX LABS	25MG	N09458 001

CROMOLYN SODIUM

CONCENTRATE; ORAL
GASTROCROM
* MEDEVA 100MG/5ML N20479 001 FEB 29, 1996

SOLUTION; INHALATION
CROMOLYN SODIUM
AN STERIPAK 10MG/ML N75271 001 JAN 18, 2000
AN WARRICK PHARMS 10MG/ML N75437 001 APR 21, 2000

SOLUTION, CONCENTRATE; ORAL
GASTROCROM
\+ MEDEVA 100MG/5ML N20479 001 FEB 29, 1996

CYANOCOBALAMIN

INJECTABLE; INJECTION
CYANOCOBALAMIN
@ AVENTIS PHARMS 1MG/ML N80564 001
AP HOECHST MARION RSSL 1MG/ML N80564 001

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
CYCLOPENTOLATE HCL
AT ALCON UNIVERSAL 1% N89162 001 JAN 24, 1991
AT STERIS 1% N89162 001 JAN 24, 1991

CYCLOSPORINE

CAPSULE; ORAL
CYCLOSPORINE
AB ABBOTT 25MG N65003 001 MAY 12, 2000
AB 50MG N65003 002 MAY 12, 2000
AB 100MG N65003 003 MAY 12, 2000

CYCLOSPORINE

CAPSULE; ORAL
CYCLOSPORINE
AB EON 25MG N65017 002 JAN 13, 2000
AB 100MG N65017 001 JAN 13, 2000

NEORAL
AB NOVARTIS 25MG N50715 001 JUL 14, 1995
AB 50MG N50715 003 JUL 14, 1995
AB + 100MG N50715 002 JUL 14, 1995
BX 25MG N50715 001 JUL 14, 1995
BX 50MG N50715 003 JUL 14, 1995
BX + 100MG N50715 002 JUL 14, 1995

SOLUTION; ORAL
CYCLOSPORINE
AB ABBOTT 100MG/ML N65025 001 MAR 03, 2000

SANGCYA
AB SANGSTAT MEDCL 100MG/ML N64195 001 OCT 31, 1998
@ 100MG/ML N64195 001 OCT 31, 1998

DAUNORUBICIN CITRATE

INJECTABLE, LIPOSOMAL; INJECTION
DAUNOXOME
\+ GILEAD EQ 2MG BASE/ML N50704 002 APR 08, 1996
\+ NEXSTAR EQ 2MG BASE/ML N50704 002 APR 08, 1996

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
DAUNORUBICIN HCL
AP + BEDFORD EQ 5MG BASE/ML N50731 001 JAN 30, 1998

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
DAUNORUBICIN HCL

	*	BEDFORD	EQ 5MG BASE/ML	N50731 001 JAN 30, 1998
AP		GENSIA SICOR PHARMS	EQ 5MG BASE/ML	N65035 001 JAN 24, 2000
	+		EQ 50MG BASE/VIAL	N64212 002 MAY 03, 1999

DEMECLOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL
DECLOMYCIN

	*	LEDERLE	150MG	N50262 001
	@		150MG	N50262 001

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION
DESMOPRESSIN ACETATE

AP		BEDFORD	0.004MG/ML	N74575 001 FEB 18, 2000

DESMOPRESSIN ACETATE PRESERVATIVE FREE

AP		BEDFORD	0.004MG/ML	N74574 001 FEB 18, 2000

SPRAY, METERED; NASAL
STIMATE

	+	AVENTIS BEHRING	0.15MG/SPRAY	N20355 001 MAR 07, 1994
	*	CENTEON	0.15MG/SPRAY	N20355 001 MAR 07, 1994

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28
MIRCETTE

> DLT >	*	ORGANON	0.15MG;0.02MG	N20713 001 APR 22, 1998
> ADD >	+		0.15MG,N/A;0.02MG,0.01MG	N20713 001 APR 22, 1998

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OPHTHALMIC
NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE

AT	ALCON UNIVERSAL	0.1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N62721 001 NOV 17, 1986
AT	STERIS	0.1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N62721 001 NOV 17, 1986

DEXAMETHASONE SODIUM PHOSPHATE

SOLUTION/DROPS; OPHTHALMIC, OTIC
DEXAMETHASONE SODIUM PHOSPHATE

AT	ALCON UNIVERSAL	EQ 0.1% PHOSPHATE	N88771 001 JAN 16, 1985

SOLUTION/DROPS; OPHTHALMIC, OTIC
DEXAMETHASONE SODIUM PHOSPHATE

AT	STERIS	EQ 0.1% PHOSPHATE	N88771 001 JAN 16, 1985

DEXAMETHASONE SODIUM PHOSPHATE; NEOMYCIN SULFATE

SOLUTION/DROPS; OPHTHALMIC
NEOMYCIN SULFATE-DEXAMETHASONE SODIUM PHOSPHATE

AT	ALCON UNIVERSAL	EQ 0.1% PHOSPHATE; EQ 3.5MG BASE/ML	N62714 001 JUL 21, 1986
AT	STERIS	EQ 0.1% PHOSPHATE; EQ 3.5MG BASE/ML	N62714 001 JUL 21, 1986

DEZOCINE

INJECTABLE; INJECTION
DALGAN

> DLT >	*	ASTRAZENECA	5MG/ML	N19082 001 DEC 29, 1989
> DLT >	*		10MG/ML	N19082 002 DEC 29, 1989
> DLT >	*		15MG/ML	N19082 003 DEC 29, 1989
> ADD >	@		5MG/ML	N19082 001 DEC 29, 1989

DEZOCINE

INJECTABLE; INJECTION
DALGAN

>ADD>	@	ASTRAZENECA	10MG/ML	N19082 002 DEC 29, 1989
>ADD>	@		15MG/ML	N19082 003 DEC 29, 1989

DICLOFENAC POTASSIUM

TABLET; ORAL
DICLOFENAC POTASSIUM

AB		GENEVA PHARMS TECH	50MG	N75229 001 NOV 20, 1998
AB		INVAMED	50MG	N75229 001 NOV 20, 1998

DICLOFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC
DICLOFENAC SODIUM

AB		FALCON PHARMS	0.1% †	N20809 001 MAY 04, 1998
	@		0.1%	N20809 001 MAY 04, 1998

VOLTAREN

AB	*	CIBA	0.1%	N20037 001 MAR 28, 1991
	+		0.1%	N20037 001 MAR 28, 1991

TABLET, EXTENDED RELEASE; ORAL
DICLOFENAC SODIUM

AB		BIOVAIL	100MG	N75492 001 FEB 11, 2000

VOLTAREN-XR

AB	+	NOVARTIS	100MG	N20254 001 MAR 08, 1996
	*		100MG	N20254 001 MAR 08, 1996

DIENESTROL

SUPPOSITORY; VAGINAL
DV

	@	AVENTIS PHARMS	0.7MG	N83517 001

† SEE SECTION 1.3 OF INTRODUCTION

DIENESTROL

SUPPOSITORY; VAGINAL
DV

	*	HOECHST MARION RSSL	0.7MG	N83517 001

DIFLORASONE DIACETATE

CREAM; TOPICAL
DIFLORASONE DIACETATE

AB		TARO	0.05%	N75508 001 APR 24, 2000

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
DILTIAZEM HCL

AB3		BIOVAIL	120MG	N20939 001 JAN 28, 2000
AB3			180MG	N20939 002 JAN 28, 2000
AB3			240MG	N20939 003 JAN 28, 2000
AB3			300MG	N20939 004 JAN 28, 2000

INJECTABLE; INJECTION
DILTIAZEM HCL

AP		ABBOTT	5MG/ML	N75004 001 FEB 16, 2000

DILTIAZEM MALATE

TABLET, EXTENDED RELEASE; ORAL
TIAMATE

	*	HOECHST MARION RSSL	EQ 120MG HCL	N20506 001 OCT 04, 1996
	*		EQ 180MG HCL	N20506 002 OCT 04, 1996
	*		EQ 240MG HCL	N20506 003 OCT 04, 1996
	+	MERCK	EQ 120MG HCL	N20506 001 OCT 04, 1996
	+		EQ 180MG HCL	N20506 002 OCT 04, 1996

† SEE SECTION 1.3 OF INTRODUCTION

DILTIAZEM MALATE

TABLET, EXTENDED RELEASE; ORAL
TIAMATE
+ MERCK — EQ 240MG HCL — N20506 003 OCT 04, 1996

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL
DIPHENHYDRAMINE HCL
AA GLOBAL PHARM — 25MG — N80807 001
AA — 50MG — N80807 002
IMPAX LABS — 25MG — N80807 001
@ — 50MG — N80807 002

DOXEPIN HYDROCHLORIDE

CREAM; TOPICAL
ZONALON
+ BIOGLAN PHAR — 5% — N20126 001 APR 01, 1994
+ MEDICIS — 5% — N20126 001 APR 01, 1994

DOXERCALCIFEROL

INJECTABLE; INJECTION
HECTOROL
+ BONE CARE — 2 UGM/ML — N21027 001 APR 06, 2000

DOXYCYCLINE

CAPSULE; ORAL
DOXYCYCLINE
AB EON — EQ 50MG BASE — N65032 001 JUN 30, 2000
AB — EQ 100MG BASE — N65032 002 JUN 30, 2000
AB HALSEY — EQ 50MG BASE — N65041 001 APR 28, 2000
AB — EQ 100MG BASE — N65041 002 APR 28, 2000

DOXYCYCLINE

CAPSULE; ORAL
MONODOX
AB OCLASSEN — EQ 50MG BASE — N50641 002 FEB 10, 1992
AB + — EQ 100MG BASE — N50641 001 DEC 29, 1989
EQ 50MG BASE — N50641 002 FEB 10, 1992
+ EQ 100MG BASE — N50641 001 DEC 29, 1989

> ADD > EFLORNITHINE HYDROCHLORIDE

> ADD > CREAM; TOPICAL
> ADD > VANIQA
> ADD > + WESTWOOD SQUIBB CLTN — 13.9% — N21145 001 JUL 27, 2000
> ADD >

ENFLURANE

LIQUID; INHALATION
ETHRANE
AN + BAXTER PHARM PROD — 99.9% — N17087 001
AN + OHMEDA — 99.9% — N17087 001

ERGOTAMINE TARTRATE

TABLET; SUBLINGUAL
ERGOMAR
AA LOTUS BIOCHEM — 2MG — N87693 001 FEB 24, 1983
+ — 2MG — N87693 001 FEB 24, 1983
ERGOSTAT
AA PARKE DAVIS — 2MG — N88337 001 JUN 08, 1984
@ — 2MG — N88337 001 JUN 08, 1984
WIGRETTES
AA + ORGANON — 2MG — N86750 001 JUL 29, 1982
@ — 2MG — N86750 001 JUL 29, 1982

ERYTHROMYCIN

SOLUTION; TOPICAL

SANSAC

AT		GALDERMA LABS	2%	N62522 001 JAN 24, 1985
AT		HEALTHPOINT	2%	N62522 001 JAN 24, 1985

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE; ORAL

PEDIAMYCIN

AB		ROSS LABS	EQ 200MG BASE/5ML	N62305 001
	@		EQ 200MG BASE/5ML	N62305 001

SUSPENSION/DROPS; ORAL

PEDIAMYCIN

	*	ROSS LABS	EQ 100MG BASE/2.5ML	N62305 002
	@		EQ 100MG BASE/2.5ML	N62305 002

TABLET, CHEWABLE; ORAL

PEDIAMYCIN

AB		ROSS LABS	EQ 200MG BASE	N62306 001
	@		EQ 200MG BASE	N62306 001

ESTRADIOL

CREAM; VAGINAL

ESTRACE

	*	BRISTOL MYERS SQUIBB	0.01%	N86069 001 JAN 31, 1984
	+	WARNER CHILCOTT	0.01%	N86069 001 JAN 31, 1984

FILM, EXTENDED RELEASE; TRANSDERMAL

CLIMARA

AB	+	BERLEX LABS	0.05MG/24HR	N20375 001 DEC 22, 1994
AB	+		0.1MG/24HR	N20375 002 DEC 22, 1994
BX	+		0.05MG/24HR	N20375 001 DEC 22, 1994
BX	+		0.1MG/24HR	N20375 002 DEC 22, 1994

ESTRADIOL

BX		CYGNUS CA	0.05MG/24HR	N21048 001 SEP 20, 1999

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL

ESTRADIOL

BX		CYGNUS CA	0.075MG/24HR	N21048 002 SEP 20, 1999
BX			0.1MG/24HR	N21048 003 SEP 20, 1999
	@	JOHNSON RW	0.05MG/24HR	N21048 001 SEP 20, 1999
	@		0.075MG/24HR	N21048 002 SEP 20, 1999
	@		0.1MG/24HR	N21048 003 SEP 20, 1999
AB		MYLAN TECHNOLOGIES	0.05MG/24HR	N75233 001 FEB 24, 2000
AB			0.1MG/24HR	N75182 001 FEB 24, 2000

TABLET; ORAL

ESTRADIOL

AB		APPLIED ANAL	0.5MG	N40138 001 JAN 30, 1998
AB			1MG	N40138 002 JAN 30, 1998
AB			2MG	N40138 003 JAN 30, 1998
AB		ENDEAVOR	0.5MG	N40138 001 JAN 30, 1998
AB			1MG	N40138 002 JAN 30, 1998
AB			2MG	N40138 003 JAN 30, 1998

ETHANOLAMINE OLEATE

INJECTABLE; INJECTION

ETHAMOLIN

	*	CYPROS	50MG/ML	N19357 001 DEC 22, 1988
	+	QUESTCOR PHARM	50MG/ML	N19357 001 DEC 22, 1988

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-21
TRIVORA-21

AB	SEARLE	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	N74538 001 DEC 18, 1997	
AB	WATSON LABS	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	N74538 001 DEC 18, 1997	

TABLET; ORAL-28
TRIVORA-28

AB	SEARLE	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	N74538 002 DEC 18, 1997	
AB	WATSON LABS	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	N74538 002 DEC 18, 1997	

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21
OVCON-35

*	BRISTOL MYERS SQUIBB	0.035MG;0.4MG	N18127 001	
+	WARNER CHILCOTT	0.035MG;0.4MG	N18127 001	

OVCON-50

@	BRISTOL MYERS SQUIBB	0.05MG;1MG	N18128 001	
@	WARNER CHILCOTT	0.05MG;1MG	N18128 001	

TABLET; ORAL-28
OVCON-35

	BRISTOL MYERS SQUIBB	0.035MG;0.4MG	N17716 001	
	WARNER CHILCOTT	0.035MG;0.4MG	N17716 001	

OVCON-50

	BRISTOL MYERS SQUIBB	0.05MG;1MG	N17576 001	
	WARNER CHILCOTT	0.05MG;1MG	N17576 001	

ETODOLAC

CAPSULE; ORAL
ETODOLAC

> ADD >	AB	TORPHARM	200MG	N75419 001 JUL 28, 2000	
> ADD >					
> ADD >	AB		300MG	N75419 002 JUL 28, 2000	
> ADD >					

ETODOLAC

TABLET; ORAL
ETODOLAC

AB	TARO PHARM INDS	500MG	N75074 002 APR 25, 2000	

TABLET, EXTENDED RELEASE; ORAL
ETODOLAC

> ADD >	AB	TEVA	500MG	N75665 002 JUL 31, 2000	
> ADD >					
> ADD >	AB		600MG	N75665 001 JUL 31, 2000	
> ADD >					
> ADD >	AB	WHITNEY PHARMS	400MG	N75696 001 JUL 31, 2000	
> ADD >					

LODINE XL

> ADD >	AB	+ WYETH AYERST	400MG	N20584 001 OCT 25, 1996	
> ADD >					
> ADD >	AB	+	500MG	N20584 003 JAN 20, 1998	
> ADD >					
> ADD >	AB	+	600MG	N20584 002 OCT 25, 1996	
> ADD >					
> DLT >		*	400MG	N20584 001 OCT 25, 1996	
> DLT >					
> DLT >		*	500MG	N20584 003 JAN 20, 1998	
> DLT >					
> DLT >		*	600MG	N20584 002 OCT 25, 1996	
> DLT >					

FENOLDOPAM MESYLATE

INJECTABLE; INJECTION
CORLOPAM

+	ABBOTT	EQ 10MG BASE/ML	N19922 001 SEP 23, 1997	
*	ELAN PHARMA	EQ 10MG BASE/ML	N19922 001 SEP 23, 1997	

FENTANYL CITRATE

INJECTABLE; INJECTION
SUBLIMAZE PRESERVATIVE FREE

AP	+ AKORN MFG	EQ 0.05MG BASE/ML	N16619 001	
AP	* JANSSEN	EQ 0.05MG BASE/ML	N16619 001	

FEXOFENADINE HYDROCHLORIDE

TABLET; ORAL
ALLEGRA
AVENTIS PHARMS — 30MG — N20872 001 FEB 25, 2000
60MG — N20872 002 FEB 25, 2000
+ 180MG — N20872 004 FEB 25, 2000

FLOXURIDINE

INJECTABLE; INJECTION
FLOXURIDINE
AP BEDFORD — 500MG/VIAL — N75387 001 APR 16, 2000

FUDR
AP + ROCHE — 500MG/VIAL — N16929 001
* 500MG/VIAL N16929 001

FLUCONAZOLE

TABLET; ORAL
DIFLUCAN
PFIZER — 150MG — N20322 001 JUN 30, 1994
150MG — N19949 004 JUN 30, 1994

FLUMAZENIL

INJECTABLE; INJECTION
ROMAZICON
+ HLR — 0.1MG/ML — N20073 001 DEC 20, 1991
* ROCHE 0.1MG/ML N20073 001 DEC 20, 1991

FLUOROURACIL

INJECTABLE; INJECTION
FLUOROURACIL
AP GENSIA SICOR PHARMS — 50MG/ML — N40333 001 JAN 27, 2000

> ADD >
> ADD >
> ADD >
> ADD >
> ADD >

FLUOROURACIL

INJECTABLE; INJECTION
FLUOROURACIL
AP GENSIA SICOR PHARMS — 50MG/ML — N40334 001 FEB 25, 2000

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL
SARAFEM
LILLY — EQ 10MG BASE — N18936 007 JUL 06, 2000
+ EQ 20MG BASE — N18936 008 JUL 06, 2000

FURAZOLIDONE

SUSPENSION; ORAL
FUROXONE
+ ROBERTS LABS — 50MG/15ML — N11323 002
+ SHIRE LABS — 50MG/15ML — N11323 002

TABLET; ORAL
FUROXONE
+ ROBERTS LABS — 100MG — N11270 002
+ SHIRE LABS — 100MG — N11270 002

GABAPENTIN

SOLUTION; ORAL
NEURONTIN
+ PARKE DAVIS — 250MG/5ML — N21129 001 MAR 02, 2000

GADOPENTETATE DIMEGLUMINE

INJECTABLE; INJECTION
MAGNEVIST
+ BERLEX LABS — 469.01MG/ML — N21037 001 MAR 10, 2000

GEMTUZUMAB OZOGAMICIN

INJECTABLE; INJECTION
MYLOTARG
+ WYETH AYERST 5MG/VIAL N21174 001 MAY 17, 2000

GENTAMICIN SULFATE

INJECTABLE; INJECTION
GARAMYCIN
AP * SCHERING EQ 10MG BASE/ML N61739 001
@ EQ 10MG BASE/ML N61739 001
GENTAMICIN SULFATE
AP ELKINS SINN EQ 10MG BASE/ML N62251 002
AP + EQ 10MG BASE/ML N62251 002

SOLUTION/DROPS; OPHTHALMIC
GENTAMICIN SULFATE
AT ALCON UNIVERSAL EQ 0.3% BASE N62523 001 NOV 25, 1985
AT STERIS EQ 0.3% BASE N62523 001 NOV 25, 1985

GLYBURIDE

TABLET; ORAL
GLYBURIDE (MICRONIZED)
AB AVENTIS PHARMS 6MG N20055 003 MAR 08, 2000

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL
GLUCOVANCE
BRISTOL MYERS SQUIBB 1.25MG;250MG N21178 001 JUL 31, 2000
2.5MG;500MG N21178 002 JUL 31, 2000
5MG;500MG N21178 003 JUL 31, 2000
+

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN
AT IPHARM 0.025MG/ML;EQ 1.75MG BASE/ML; 10,000 UNITS/ML N62818 001 OCT 11, 1988
@ 0.025MG/ML;EQ 1.75MG BASE/ML; 10,000 UNITS/ML N62818 001 OCT 11, 1988

GREPAFLOXACIN HYDROCHLORIDE

TABLET; ORAL
RAXAR
GLAXO WELLCOME EQ 200MG BASE N20695 001 NOV 06, 1997
EQ 400MG BASE N20695 002 MAY 14, 1998
EQ 600MG BASE N20695 003 MAY 14, 1998
*
OTSUKA EQ 200MG BASE N20695 001 NOV 06, 1997
EQ 400MG BASE N20695 002 MAY 14, 1998
EQ 600MG BASE N20695 003 MAY 14, 1998
+

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

TABLET; ORAL
GRIS-PEG
AB ALLERGAN HERBERT 125MG N50475 001
AB 250MG N50475 002
AB PEDINOL 125MG N50475 001
AB 250MG N50475 002

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION
HALOPERIDOL DECANOATE
AO APOTEX EQ 50MG BASE/ML N75440 001 FEB 28, 2000
AO EQ 100MG BASE/ML N75440 002 FEB 28, 2000

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION
HALOPERIDOL DECANOATE

AO	KING PHARMS	EQ 50MG BASE/ML	N75176 001		FEB 09, 2000
AO		EQ 100MG BASE/ML	N75176 002		FEB 09, 2000

HEPARIN SODIUM

INJECTABLE; INJECTION
HEPARIN LOCK FLUSH

@	STERIS	100 UNITS/ML	N17064 001		N17064 001
@		100 UNITS/ML	N17064 001		

HEPARIN SODIUM

AP	STERIS	5,000 UNITS/ML	N17064 003		N17064 003
AP		10,000 UNITS/ML	N17064 004		N17064 004
AP		20,000 UNITS/ML	N17064 005		N17064 005
AP		40,000 UNITS/ML	N17064 006		N17064 006
@		5,000 UNITS/ML	N17064 003		
@		10,000 UNITS/ML	N17064 004		
@		20,000 UNITS/ML	N17064 005		
@		40,000 UNITS/ML	N17064 006		

HISTRELIN ACETATE

INJECTABLE; INJECTION
SUPPRELIN

+	ROBERTS LABS	EQ 0.2MG BASE/ML	N19836 001		DEC 24, 1991
+		EQ 0.5MG BASE/ML	N19836 002		DEC 24, 1991
+		EQ 1MG BASE/ML	N19836 003		DEC 24, 1991
+	SHIRE LABS	EQ 0.2MG BASE/ML	N19836 001	> DLT >	DEC 24, 1991
+		EQ 0.5MG BASE/ML	N19836 002	> ADD >	DEC 24, 1991
+		EQ 1MG BASE/ML	N19836 003	> ADD >	DEC 24, 1991

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
HYDRALAZINE HCL

AP	GENSIA SICOR PHARMS	20MG/ML	N40373 001		FEB 23, 2000
AP	+ LUITPOLD	20MG/ML	N40136 001		JUN 30, 1997
*		20MG/ML	N40136 001		JUN 30, 1997

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL
HYDROCHLOROTHIAZIDE

AB	MYLAN	12.5MG	N75640 001		JAN 28, 2000

MICROZIDE

AB	+ WATSON LABS	12.5MG	N20504 001		DEC 27, 1996
*		12.5MG	N20504 001		DEC 27, 1996

TABLET; ORAL
HYDROCHLOROTHIAZIDE

AB	GLOBAL PHARM	100MG	N85098 001		
@	IMPAX LABS	100MG	N85098 001		

HYDROCORTISONE

CREAM; TOPICAL
HYDROCORTISONE

AT	ZENITH GOLDLINE	1%	N85733 001		
@		1%	N85733 001		

NOGENIC HC

AT	ZENITH GOLDLINE	1%	N87427 001		APR 04, 1988
@		1%	N87427 001		APR 04, 1988

NUTRACORT

AT	GALDERMA LABS	0.5%	N80442 002		
AT		1%	N80442 003		
AT	HEALTHPOINT	1%	N80442 003		
@		0.5%	N80442 002		

GEL; TOPICAL
NUTRACORT

@	GALDERMA LABS	1%	N84698 001		

HYDROCORTISONE

GEL; TOPICAL
NUTRACORT
@ HEALTHPOINT 1% N84698 001

LOTION; TOPICAL
HYDROCORTISONE
> ADD > AT ALTANA 2.5% N40351 001
> ADD > JUL 25, 2000
NUTRACORT
AT GALDERMA LABS 0.5% N80443 002
AT 1% N80443 003
AT 2.5% N87644 001
AUG 24, 1982
AT HEALTHPOINT 1% N80443 003
AT 2.5% N87644 001
AUG 24, 1982
@ 0.5% N80443 002

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OPHTHALMIC
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE
AT ALCON UNIVERSAL 1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML N62874 001
MAY 11, 1988
AT STERIS 1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML N62874 001
MAY 11, 1988

SUSPENSION/DROPS; OTIC
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE
AT ALCON UNIVERSAL 1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML N62488 001
NOV 06, 1985
AT STERIS 1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML N62488 001
NOV 06, 1985

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

AEROSOL, METERED; TOPICAL
EPIFOAM
BX SCHWARZ PHARMA 1%;1% N86457 001
PROCTOFOAM HC
BX SCHWARZ PHARMA 1%;1% N86195 001

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

DISC; TOPICAL
EPIFOAM
BX SCHWARZ PHARMA 1%;1% N86457 001
PROCTOFOAM HC
BX SCHWARZ PHARMA 1%;1% N86195 001

HYDROCORTISONE BUTYRATE

CREAM; TOPICAL
LOCOID
@ GALDERMA LABS 0.1% N18795 001
JAN 07, 1983
@ YAMANOUCHI 0.1% N18795 001
JAN 07, 1983

OINTMENT; TOPICAL
LOCOID
@ GALDERMA LABS 0.1% N19106 001
JUL 03, 1984
@ YAMANOUCHI 0.1% N19106 001
JUL 03, 1984

SOLUTION; TOPICAL
LOCOID
@ GALDERMA LABS 0.1% N19819 001
SEP 15, 1988
@ YAMANOUCHI 0.1% N19819 001
SEP 15, 1988

HYDROCORTISONE VALERATE

CREAM; TOPICAL
HYDROCORTISONE VALERATE
AB CLAY PARK 0.2% N75666 001
MAY 24, 2000

HYDROXYUREA

CAPSULE; ORAL
HYDROXYUREA
DURAMED 250MG N75020 002
JUN 26, 2000

INSULIN ASPART RECOMBINANT

INJECTABLE; INJECTION
NOVOLOG
+ NOVO NORDISK — 100 UNITS/ML — N20986 001 JUN 07, 2000

INSULIN GLARGINE

INJECTABLE; INJECTION
LANTUS
+ AVENTIS PHARMS — 100 UNITS/ML — N21081 001 APR 20, 2000

INSULIN LISPRO; INSULIN LISPRO PROTAMINE

INJECTABLE; INJECTION
HUMALOG MIX 50/50
+ LILLY — 50 UNITS/ML;50 UNITS/ML — N21018 001 DEC 22, 1999

HUMALOG MIX 75/25
+ LILLY — 25 UNITS/ML;75 UNITS/ML — N21017 001 DEC 22, 1999

INSULIN LISPRO PROTAMINE

INJECTABLE; INJECTION
HUMALOG MIX 50/50
* LILLY — 100 UNITS/ML — N21018 001 DEC 22, 1999

HUMALOG MIX 75/25
* LILLY — 100 UNITS/ML — N21017 001 DEC 22, 1999

INULIN

INJECTABLE; INJECTION
INULIN AND SODIUM CHLORIDE
* CYPROS — 100MG/ML — N02282 001
+ QUESTCOR PHARM — 100MG/ML — N02282 001

IOPAMIDOL

INJECTABLE; INJECTION
IOPAMIDOL-200
> ADD > AP COOK IMAGING 41% N74881 001 JUL 28, 2000
> ADD >

IOPAMIDOL-250
> ADD > AP COOK IMAGING 51% N74881 002 JUL 28, 2000
> ADD >

IOPAMIDOL-300
> ADD > AP COOK IMAGING 61% N74881 003 JUL 28, 2000
> ADD >

IOPAMIDOL-370
> ADD > AP COOK IMAGING 76% N74881 004 JUL 28, 2000
> ADD >

IOTHALAMATE SODIUM, I-125

INJECTABLE; INJECTION
GLOFIL-125
CYPROS 250-300 uCi/ML N17279 001
QUESTCOR PHARM 250-300 uCi/ML N17279 001

IPRATROPIUM BROMIDE

SOLUTION; INHALATION
IPRATROPIUM BROMIDE
AN STERIPAK 0.02% N75313 001 FEB 07, 2000

> ADD > ISOCARBOXAZID

> ADD > TABLET; ORAL
> ADD > MARPLAN
> ADD > + OXFORD PHARM 10MG N11961 001

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION
> DLT > BRONKOSOL
> DLT > AN * SANOFI SYNTHELABO 1% N12339 008
> ADD > @ 1% N12339 008
ISOETHARINE HCL
> DLT > AN ROXANE 1% N86899 001
> ADD > AN + 1% N86899 001

ISOETHARINE MESYLATE

AEROSOL, METERED; INHALATION

> DLT >		BRONKOMETER		
> DLT >	*	SANOFI SYNTHELABO	0.34MG/INH	N12339 007
> ADD >	@		0.34MG/INH	N12339 007

ISOPROTERENOL HYDROCHLORIDE

AEROSOL, METERED; INHALATION

		ISUPREL		
	*	SANOFI SYNTHELABO	0.103MG/INH	N11178 001
	@		0.103MG/INH	N11178 001

SOLUTION; INHALATION

		ISUPREL		
	*	SANOFI SYNTHELABO	0.5%	N06327 002
	*		1%	N06327 003
	@		0.5%	N06327 002
	@		1%	N06327 003

ISOSORBIDE DINITRATE

TABLET, EXTENDED RELEASE; ORAL

		ISORDIL		
AB	*	WYETH AYERST	40MG	N12882 001 JUL 29, 1988
	@		40MG	N12882 001 JUL 29, 1988
		ISOSORBIDE DINITRATE		
AB		INWOOD LABS	40MG	N40009 001 DEC 30, 1998
	+		40MG	N40009 001 DEC 30, 1998

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE; ORAL

		IMDUR		
AB	+	SCHERING	120MG	N20225 003 MAR 30, 1995
	*		120MG	N20225 003 MAR 30, 1995
		ISOSORBIDE MONONITRATE		
AB		DEXCEL LTD	60MG	N75522 001 APR 17, 2000

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE; ORAL

		ISOSORBIDE MONONITRATE		
AB		KREMERS URBAN	30MG	N75155 002 JAN 13, 2000
AB		KV PHARM	30MG	N75395 001 MAR 16, 2000
AB			60MG	N75395 002 MAR 16, 2000
AB			120MG	N75395 003 MAR 16, 2000
AB		ZENITH GOLDLINE	60MG	N75448 001 JUN 19, 2000

KETOCONAZOLE

CREAM; TOPICAL

		KETOCONAZOLE		
AB		TEVA	2%	N75581 001 APR 25, 2000
		NIZORAL		
AB	+	MCNEIL CONS	2%	N19084 001 DEC 31, 1985
	*		2%	N19084 001 DEC 31, 1985

SHAMPOO; TOPICAL

		NIZORAL		
	*	JANSSEN	2%	N19927 001 AUG 31, 1990
	+	MCNEIL CONS	2%	N19927 001 AUG 31, 1990

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

		LEUCOVORIN CALCIUM PRESERVATIVE FREE		
AP	+	ABBOTT	EQ 10MG BASE/ML	N40147 001 JUN 25, 1997
	*		EQ 10MG BASE/ML	N40147 001 JUN 25, 1997
AP		BEDFORD	EQ 10MG BASE/ML	N40347 001 APR 25, 2000
AP			EQ 350MG BASE/VIAL	N40335 001 APR 20, 2000

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

> DLT > > DLT > > DLT > > ADD > > ADD >

WELLCOVORIN

AP GLAXO WELLCOME — EQ 100MG BASE/VIAL — N89834 001 JAN 23, 1989

@ — EQ 100MG BASE/VIAL — N89834 001 JAN 23, 1989

LEUPROLIDE ACETATE

IMPLANT; IMPLANTATION

VIADUR

+ ALZA — EQ 65MG BASE — N21088 001 MAR 03, 2000

LEVOBETAXOLOL HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC

BETAXON

+ ALCON — EQ 0.5% BASE — N21114 001 FEB 23, 2000

LEVOBUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CHIROCAINE

DARWIN DISCOVERY — EQ 2.5MG BASE/ML — N20997 001 AUG 05, 1999

EQ 5MG BASE/ML — N20997 002 AUG 05, 1999

+ EQ 7.5MG BASE/ML — N20997 003 AUG 05, 1999

PURDUE PHARMA — EQ 2.5MG BASE/ML — N20997 001 AUG 05, 1999

EQ 5MG BASE/ML — N20997 002 AUG 05, 1999

+ EQ 7.5MG BASE/ML — N20997 003 AUG 05, 1999

LEVORPHANOL TARTRATE

TABLET; ORAL

LEVO-DROMORAN

AB + ICN — 2MG — N08720 001 DEC 19, 1991

LEVORPHANOL TARTRATE

TABLET; ORAL

LEVO-DROMORAN

+ ICN — 2MG — N08720 001 DEC 19, 1991

LEVORPHANOL TARTRATE

AB ROXANE — 2MG — N74278 001 MAR 31, 2000

LINEZOLID

GRANULE, FOR RECONSTITUTION; ORAL

ZYVOX

+ PHARMACIA AND UPJOHN 100MG/5ML — N21132 001 APR 18, 2000

INJECTABLE; INJECTION

ZYVOX

+ PHARMACIA AND UPJOHN 200MG/100ML — N21131 001 APR 18, 2000

TABLET; ORAL

ZYVOX

PHARMACIA AND UPJOHN 400MG — N21130 001 APR 18, 2000

+ 600MG — N21130 002 APR 18, 2000

LORAZEPAM

INJECTABLE; INJECTION

LORAZEPAM

AP MOVA — 2MG/ML — N74793 001 MAR 16, 2000

AP — 4MG/ML — N74793 002 MAR 16, 2000

MAGNESIUM SULFATE

INJECTABLE; INJECTION

MAGNESIUM SULFATE

AP ABBOTT — 500MG/ML — N75151 001 APR 25, 2000

AP + AM PHARM PARTNERS — 500MG/ML — N19316 001 SEP 08, 1986

MAGNESIUM SULFATE

INJECTABLE; INJECTION
MAGNESIUM SULFATE

*	AM PHARM PARTNERS	500MG/ML	N19316 001 SEP 08, 1986		

MEDROXYPROGESTERONE ACETATE

TABLET; ORAL
AMEN

BP	AMARIN PHARMS	10MG	N83242 001		
BP	CARNRICK	10MG	N83242 001		

MEGESTROL ACETATE

TABLET; ORAL
MEGESTROL ACETATE

AB	PHARMACHEMIE	40MG	N74745 001 FEB 27, 1998		
AB	TEVA	40MG	N74745 001 FEB 27, 1998	> DLT > > DLT > > ADD > > ADD > > DLT > > DLT > > DLT > > DLT > > ADD > > ADD >	

MELOXICAM

TABLET; ORAL
MOBIC

+	BOEHRINGER INGELHEIM	7.5MG	N20938 001 APR 13, 2000		

MENOTROPINS (FSH;LH)

INJECTABLE; INJECTION
MENOTROPINS

@	FERRING	75 IU/VIAL;75 IU/VIAL	N73598 001 JAN 30, 1997		
@		150 IU/VIAL;150 IU/VIAL	N73599 001 JAN 30, 1997		

REPRONEX

AB	FERRING	75 IU/VIAL;75 IU/VIAL	N73598 001 JAN 30, 1997		
AB		150 IU/VIAL;150 IU/VIAL	N73599 001 JAN 30, 1997		

MEPERIDINE HYDROCHLORIDE

TABLET; ORAL
MEPERIDINE HCL

AA	MALLINCKRODT	50MG	N40352 001 JUN 13, 2000		
AA		100MG	N40352 002 JUN 13, 2000		

MEPHENTERMINE SULFATE

INJECTABLE; INJECTION
WYAMINE SULFATE

*	WYETH AYERST	EQ 30MG BASE/ML	N08248 001		
@		EQ 30MG BASE/ML	N08248 001		

MESALAMINE

CAPSULE, EXTENDED RELEASE; ORAL
PENTASA

*	ROBERTS LABS	250MG	N20049 001 MAY 10, 1993		
+	SHIRE LABS	250MG	N20049 001 MAY 10, 1993		

SUPPOSITORY; RECTAL
ROWASA

*	SOLVAY	500MG	N19919 001 DEC 18, 1990		
@		500MG	N19919 001 DEC 18, 1990		

MESTRANOL; NORETHINDRONE

TABLET; ORAL-20
NORINYL

@	SEARLE	0.1MG;2MG	N13625 004		
@	WATSON LABS	0.1MG;2MG	N13625 004		

TABLET; ORAL-21
NORINYL 1+50 21-DAY

AB	SEARLE	0.05MG;1MG	N13625 002		
AB	WATSON LABS	0.05MG;1MG	N13625 002		

METAPROTERENOL SULFATE

SOLUTION; INHALATION

		ALUPENT		
AN	*	BOEHRINGER INGELHEIM	5%	N17659 001
	+		5%	N17659 001
		PROMETA		
AN		NURO	5%	N73340 001 MAR 30, 1992
	@		5%	N73340 001 MAR 30, 1992

SYRUP; ORAL

		METAPROTERENOL SULFATE		
AA		NOVEX	10MG/5ML	N75235 001 JAN 27, 2000

METHANTHELINE BROMIDE

TABLET; ORAL

		BANTHINE		
> DLT >	*	ROBERTS LABS	50MG	N07390 001
> ADD >	+	SHIRE LABS	50MG	N07390 001

METHIMAZOLE

TABLET; ORAL

		METHIMAZOLE		
AB		APPLIED ANAL	5MG	N40320 001 MAR 31, 2000
AB			10MG	N40320 002 MAR 31, 2000
AB		GENPHARM	5MG	N40350 001 MAR 29, 2000
AB			10MG	N40350 002 MAR 29, 2000
		TAPAZOLE		
AB		LILLY	5MG	N07517 002
AB	+		10MG	N07517 004
			5MG	N07517 002
	*		10MG	N07517 004

METHYLPHENIDATE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

		METADATE ER		
AB	+	MEDEVA	10MG	N40306 001 OCT 20, 1999
	*		10MG	N40306 001 OCT 20, 1999
		METHYLIN ER		
AB		MALLINCKRODT	10MG	N75629 001 MAY 09, 2000
AB			20MG	N75629 002 MAY 09, 2000

METHYLTESTOSTERONE

TABLET; ORAL

		ORETON METHYL		
BP		SCHERING	10MG	N03158 001
BP			25MG	N03158 002
	@		10MG	N03158 001
	@		25MG	N03158 002

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

		MIDAZOLAM HCL		
AP		ABBOTT	EQ 1MG BASE/ML	N75293 001 JUN 20, 2000
AP			EQ 1MG BASE/ML	N75409 002 JUN 20, 2000
AP			EQ 5MG BASE/ML	N75293 002 JUN 20, 2000
AP			EQ 5MG BASE/ML	N75409 001 JUN 20, 2000
AP		AESGEN	EQ 1MG BASE/ML	N75154 002 JUN 20, 2000
AP			EQ 5MG BASE/ML	N75154 001 JUN 20, 2000
AP		ASTRAZENECA PHARMS	EQ 5MG BASE/ML	N75263 001 JUN 26, 2000
AP		BAXTER PHARM PROD	EQ 1MG BASE/ML	N75324 001 JUN 20, 2000
AP			EQ 5MG BASE/ML	N75324 002 JUN 20, 2000
AP		BEDFORD	EQ 1MG BASE/ML	N75247 002 JUN 23, 2000

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION
MIDAZOLAM HCL

AP		BEDFORD	EQ 5MG BASE/ML	N75247 001 JUN 23, 2000
AP			EQ 5MG BASE/ML	N75249 001 JUN 23, 2000
AP		BEN VENUE	EQ 1MG BASE/ML	N75421 002 JUN 20, 2000
AP			EQ 5MG BASE/ML	N75421 001 JUN 20, 2000
AP			EQ 5MG BASE/ML	N75455 001 JUN 20, 2000
AP		ESI LEDERLE	EQ 1MG BASE/ML	N75243 001 JUN 20, 2000
AP			EQ 5MG BASE/ML	N75243 002 JUN 20, 2000
AP		FAULDING	EQ 1MG BASE/ML	N75396 001 JUN 20, 2000
AP			EQ 5MG BASE/ML	N75396 002 JUN 20, 2000
AP			EQ 5MG BASE/ML	N75484 001 JUN 20, 2000
AP		TAYLOR	EQ 5MG BASE/ML	N75481 001 JUN 30, 2000
AP		TAYLOR PHARMA	EQ 1MG BASE/ML	N75494 001 JUN 30, 2000
AP			EQ 5MG BASE/ML	N75494 002 JUN 30, 2000

VERSED

AP	+	ROCHE	EQ 1MG BASE/ML	N18654 002 MAY 26, 1987
AP	+		EQ 5MG BASE/ML	N18654 001 DEC 20, 1985
	*		EQ 1MG BASE/ML	N18654 002 MAY 26, 1987
	*		EQ 5MG BASE/ML	N18654 001 DEC 20, 1985

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL
MINOCYCLINE HCL

AB	+	DANBURY PHARMA	EQ 75MG BASE	N63065 002 JUN 10, 1999
	*		EQ 75MG BASE	N63065 002 JUN 10, 1999

MONTELUKAST SODIUM

TABLET, CHEWABLE; ORAL
SINGULAIR

		MERCK	EQ 4MG BASE	N20830 002 MAR 03, 2000

MORPHINE SULFATE

TABLET, EXTENDED RELEASE; ORAL
MORPHINE SULFATE

AB		ESI LEDERLE	15MG	N75407 001 JAN 28, 2000

NABUMETONE

TABLET; ORAL
NABUMETONE

AB		COPLEY PHARM	750MG	N75179 001 JUN 06, 2000
AB		TEVA	500MG	N75189 001 MAY 26, 2000

RELAFEN

AB		SMITHKLINE BEECHAM	500MG	N19583 001 DEC 24, 1991
AB	+		750MG	N19583 002 DEC 24, 1991
	*		500MG	N19583 001 DEC 24, 1991
	*		750MG	N19583 002 DEC 24, 1991

NADOLOL

TABLET; ORAL
CORGARD

AB		APOTHECON	40MG	N18063 001
AB	+		40MG	N18063 001

NAFCILLIN SODIUM

TABLET; ORAL
UNIPEN

	*	WYETH AYERST	EQ 500MG BASE	N50462 001
	@		EQ 500MG BASE	N50462 001

NALMEFENE HYDROCHLORIDE

INJECTABLE; INJECTION
REVEX
+ BAXTER PHARM PROD — EQ 0.1MG BASE/ML — N20459 001 APR 17, 1995
+ — EQ 1MG BASE/ML — N20459 002 APR 17, 1995
* ORMEDA — EQ 0.1MG BASE/ML — N20459 001 APR 17, 1995
* — EQ 1MG BASE/ML — N20459 002 APR 17, 1995

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL
PENTAZOCINE AND NALOXONE HYDROCHLORIDES
AB RANBAXY — EQ 0.5MG BASE; EQ 50MG BASE — N75523 001 MAR 17, 2000

NALTREXONE HYDROCHLORIDE

TABLET; ORAL
NALTREXONE HCL
AB EON — 50MG — N75434 001 MAR 08, 2000

NAPROXEN

TABLET, DELAYED RELEASE; ORAL
NAPROXEN
AB GENEVA PHARMS TECH — 375MG — N75061 001 FEB 18, 1998
AB — 500MG — N75061 002 FEB 18, 1998
AB INVAMED — 375MG — N75061 001 FEB 18, 1998
AB — 500MG — N75061 002 FEB 18, 1998

NIACIN

TABLET; ORAL
NIACIN
AA GLOBAL PHARM — 500MG — N83115 001

NIACIN

TABLET; ORAL
NIACIN
@ IMPAX LABS — 500MG — N83115 001
NIACOR
AA UPSHER SMITH — 500MG — N40378 001 MAY 03, 2000

NIFEDIPINE

TABLET, EXTENDED RELEASE; ORAL
ADALAT CC
AB + BAYER — 30MG — N20198 001 APR 21, 1993
BC * — 30MG — N20198 001 APR 21, 1993
NIFEDIPINE
AB ELAN PHARM — 30MG — N75128 001 MAR 10, 2000

NITROFURAZONE

CREAM; TOPICAL
FURACIN
* ROBERTS LABS — 0.2% — N83789 001
+ SHIRE LABS — 0.2% — N83789 001

OINTMENT; TOPICAL
FURACIN
AT * ROBERTS LABS — 0.2% — N05795 001
AT + SHIRE LABS — 0.2% — N05795 001

NITROGLYCERIN

TABLET; SUBLINGUAL
NITROSTAT
PARKE DAVIS — 0.3MG — N21134 001 MAY 01, 2000
— 0.4MG — N21134 002 MAY 01, 2000
+ — 0.6MG — N21134 003 MAY 01, 2000

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL

	NORTRIPTYLINE HCL		
AB	TARO	EQ 10MG BASE	N75520 004 MAY 08, 2000
AB		EQ 25MG BASE	N75520 003 MAY 08, 2000
AB		EQ 50MG BASE	N75520 001 MAY 08, 2000
AB		EQ 75MG BASE	N75520 002 MAY 08, 2000

OCTREOTIDE ACETATE

INJECTABLE; INJECTION

	SANDOSTATIN		
	NOVARTIS	EQ 0.2MG BASE/ML	N19667 004 JUN 12, 1991
		EQ 1MG BASE/ML	N19667 005 JUN 12, 1991
+		EQ 0.2MG BASE/ML	N19667 004 JUN 12, 1991
+		EQ 1MG BASE/ML	N19667 005 JUN 12, 1991

	SANDOSTATIN LAR		
	NOVARTIS	EQ 10MG BASE/VIAL	N21008 001 NOV 25, 1998
		EQ 20MG BASE/VIAL	N21008 002 NOV 25, 1998
+		EQ 10MG BASE/VIAL	N21008 001 NOV 25, 1998
+		EQ 20MG BASE/VIAL	N21008 002 NOV 25, 1998

OLANZAPINE

TABLET; ORAL

	ZYPREXA		
	LILLY	2.5MG	N20592 001 SEP 30, 1996
*		10MG	N20592 004 SEP 30, 1996
@		15MG	N20592 005 SEP 09, 1997
+		2.5MG	N20592 001 SEP 30, 1996

OLANZAPINE

TABLET; ORAL

	ZYPREXA		
	LILLY	10MG	N20592 004 SEP 30, 1996
+		15MG	N20592 005 SEP 09, 1997

TABLET, ORALLY DISINTEGRATING; ORAL

	ZYPREXA ZYDIS		
	LILLY	5MG	N21086 001 APR 06, 2000
		10MG	N21086 002 APR 06, 2000
		15MG	N21086 003 APR 06, 2000
+		20MG	N21086 004 APR 06, 2000

ORPHENADRINE CITRATE

TABLET, EXTENDED RELEASE; ORAL

	ORPHENADRINE CITRATE		
AB	EON	100MG	N40327 001 FEB 15, 2000
AB	GENEVA PHARMS TECH	100MG	N40284 001 JUN 19, 1998
AB	IMPAX PHARM	100MG	N40368 001 JUN 23, 2000
AB	INVAMED	100MG	N40284 001 JUN 19, 1998

OXCARBAZEPINE

TABLET; ORAL

	TRILEPTAL		
	NOVARTIS	150MG	N21014 001 JAN 14, 2000
		300MG	N21014 002 JAN 14, 2000
+		600MG	N21014 003 JAN 14, 2000

OXYCODONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

OXYCONTIN

BX	+	PURDUE PHARMA	10MG	N20553 001	DEC 12, 1995
	+		10MG	N20553 001	DEC 12, 1995
> ADD >	+		160MG	N20553 005	MAR 15, 2000
> ADD >					

ROXICODONE

BX		ROXANE	10MG	N20932 001	OCT 26, 1998
	#		30MG	N20932 002	OCT 26, 1998
	@		10MG	N20932 001	OCT 26, 1998
	@		30MG	N20932 002	OCT 26, 1998

PANTOPRAZOLE SODIUM

TABLET, DELAYED RELEASE; ORAL

PROTONIX

+	WYETH AYERST	EQ 40MG BASE	N20987 001	FEB 02, 2000

PEMOLINE

TABLET; ORAL

PEMOLINE

AB		AMIDE PHARM	18.75MG	N75595 001	FEB 28, 2000
AB			37.5MG	N75595 002	FEB 28, 2000
AB			75MG	N75595 003	FEB 28, 2000
AB		COPLEY PHARM	18.75MG	N75030 003	FEB 22, 2000
AB		GENEVA PHARMS TECH	18.75MG	N75286 001	DEC 27, 1999
AB			37.5MG	N75286 002	JUN 30, 1999
AB			75MG	N75286 003	JUN 30, 1999
AB		INVAMED	18.75MG	N75286 001	DEC 27, 1999

PEMOLINE

TABLET; ORAL

PEMOLINE

AB		INVAMED	37.5MG	N75286 002	JUN 30, 1999
AB			75MG	N75286 003	JUN 30, 1999
AB		VINTAGE PHARMS	18.75MG	N75328 001	APR 19, 2000
AB			37.5MG	N75328 002	APR 19, 2000
AB			75MG	N75328 003	APR 19, 2000

TABLET, CHEWABLE; ORAL

CYLERT

AB	+	ABBOTT	37.5MG	N17703 001	
	#		37.5MG	N17703 001	

PEMOLINE

> ADD >	AB		AMIDE PHARM	37.5MG	N75678 001
> ADD >					JUL 26, 2000
	AB		COPLEY PHARM	37.5MG	N75555 001
					FEB 18, 2000

PENTAMIDINE ISETHIONATE

INJECTABLE; INJECTION

PENTACARINAT

AP		ARMOUR PHARM	300MG/VIAL	N73447 001 APR 28, 1994
	@		300MG/VIAL	N73447 001 APR 28, 1994

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL

PENTOXIFYLLINE

> ADD >	AB		IMPAX LABS	400MG	N75093 001 AUG 10, 1999
> ADD >					
> DLT >	AB		IMPAX PHARM	400MG	N75093 001 AUG 10, 1999
> DLT >					

PERFLUOROPOLYMETHYLISOPROPYL ETHER; POLYTETRAFLUOROETHYLENE

PASTE; TOPICAL
SKIN EXPOSURE REDUCTION PASTE AGAINST CHEMICAL WARFARE AGENTS
+ US ARMY 50%;50% N21084 001 FEB 17, 2000

PERINDOPRIL ERBUMINE

TABLET; ORAL
ACEON
@ SOLVAY 2MG N20184 001 DEC 30, 1993
@ 4MG N20184 002 DEC 30, 1993
@ 8MG N20184 003 DEC 30, 1993
SOLVAY PHARMA 2MG N20184 001 DEC 30, 1993
4MG N20184 002 DEC 30, 1993
+ 8MG N20184 003 DEC 30, 1993

PHENDIMETRAZINE TARTRATE

TABLET; ORAL
BONTRIL PDM
AA AMARIN PHARMS 35MG N85272 001
AA CARNRICK 35MG N85272 001

PREDNISOLONE

SYRUP; ORAL
PREDNISOLONE
AA COPLEY PHARM 15MG/5ML N40322 001 JAN 19, 2000

TABLET; ORAL
PREDNISOLONE
BX GLOBAL PHARM 5MG N80780 001
@ IMPAX LABS 5MG N80780 001
BX PHOENIX LABS NY 5MG N80322 001
@ 5MG N80322 001

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION/DROPS; OPHTHALMIC
PREDNISOLONE SODIUM PHOSPHATE
AT ALCON UNIVERSAL EQ 0.11% PHOSPHATE N81043 001 OCT 24, 1991
AT EQ 0.9% PHOSPHATE N81044 001 OCT 24, 1991
AT STERIS EQ 0.11% PHOSPHATE N81043 001 OCT 24, 1991
AT EQ 0.9% PHOSPHATE N81044 001 OCT 24, 1991

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE
AT ALCON UNIVERSAL EQ 0.23% PHOSPHATE;10% N73630 001 MAY 27, 1993
AT STERIS EQ 0.23% PHOSPHATE;10% N73630 001 MAY 27, 1993

PREDNISONE

SYRUP; ORAL
LIQUID PRED
* MURO 5MG/5ML N87611 002 SEP 07, 1982
@ 5MG/5ML N87611 002 SEP 07, 1982

TABLET; ORAL
PREDNICEN-M
AB CENT PHARMS 5MG N84655 001
@ SCHWARZ PHARMA 5MG N84655 001
PREDNISONE
BX PHOENIX LABS NY 5MG N80321 001
BX 20MG N83807 001
@ 5MG N80321 001
@ 20MG N83807 001

PROCHLORPERAZINE

SUPPOSITORY; RECTAL
COMPRO
AB PADDOCK 25MG N40246 001 JUN 28, 2000

PROGESTERONE

CAPSULE; ORAL
PROMETRIUM

	SCHERING PLOUGH	100MG		N19781 001 MAY 14, 1998
		200MG		N19781 002 OCT 15, 1999
	*	300MG		N19781 003 OCT 15, 1999
	UNIMED PHARMS	100MG		N19781 001 MAY 14, 1998
	+	200MG		N19781 002 OCT 15, 1999
	@	300MG		N19781 003 OCT 15, 1999

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
PROMETHAZINE HCL

AP	ABBOTT	25MG/ML	N40372 001 JUN 08, 2000
AP		50MG/ML	N40372 002 JUN 08, 2000

PROPANTHELINE BROMIDE

TABLET; ORAL
PRO-BANTHINE

> DLT >	BP	*	ROBERTS LABS	7.5MG	N08732 003
> DLT >	BP	*		15MG	N08732 002
> ADD >	BP	+	SHIRE LABS	7.5MG	N08732 003
> ADD >	BP	+		15MG	N08732 002

PROPARACAINE HYDROCHLORIDE

SOLUTION; OPHTHALMIC
PROPARACAINE HCL

AT	TAYLOR PHARMA	0.5%	N40277 001 MAR 16, 2000

PROTOKYLOL HYDROCHLORIDE

TABLET; ORAL
VENTAIRE

	@ AVENTIS PHARMS	2MG	N83459 001
	* HOECHST MARION RSSL	2MG	N83459 001

QUINIDINE SULFATE

TABLET; ORAL
QUINIDINE SULFATE

AB	PHARMAVITE	200MG	N84627 001
	@	200MG	N84627 001

RANITIDINE HYDROCHLORIDE

TABLET; ORAL
RANITIDINE

AB	RANBAXY	EQ 150MG BASE	N75439 001 APR 19, 2000
AB		EQ 300MG BASE	N75439 002 APR 19, 2000

RESERPINE

TABLET; ORAL
RESERPINE

BP	GLOBAL PHARM	0.1MG	N09627 001
BP		0.25MG	N09627 002
	@ IMPAX LABS	0.1MG	N09627 001
	@	0.25MG	N09627 002

RIVASTIGMINE TARTRATE

CAPSULE; ORAL
EXELON

	NOVARTIS	EQ 1.5MG BASE	N20823 003 APR 21, 2000
		EQ 3MG BASE	N20823 004 APR 21, 2000
		EQ 4.5MG BASE	N20823 005 APR 21, 2000
	+	EQ 6MG BASE	N20823 006 APR 21, 2000

RIVASTIGMINE TARTRATE

SOLUTION; ORAL
EXELON
+ NOVARTIS — EQ 2MG BASE/ML — N21025 001 APR 21, 2000

SELENIUM SULFIDE

LOTION/SHAMPOO; TOPICAL
SELENIUM SULFIDE
> DLT > AT ZENITH GOLDLINE 2.5% N85777 001
> ADD > @ 2.5% N85777 001

SEVELAMER HYDROCHLORIDE

> ADD > TABLET; ORAL
> ADD > RENAGEL
> ADD > GELTEX 400MG N21179 001 JUL 12, 2000
> ADD >
> ADD > + 800MG N21179 002 JUL 12, 2000
> ADD >

SODIUM FLUORIDE, F-18

INJECTABLE; INTRAVENOUS
FLUORINE F-18
@ NYCOMED AMERSHAM — 2mCi/ML — N17042 001

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION
NORDITROPIN
NOVO NORDISK 5MG/1.5ML N21148 001 JUN 20, 2000
10MG/1.5ML N21148 002 JUN 20, 2000
+ 15MG/1.5ML N21148 003 JUN 20, 2000

SOTALOL HYDROCHLORIDE

TABLET; ORAL
BETAPACE
AB BERLEX LABS 80MG N19865 001 OCT 30, 1992
AB 120MG N19865 005 APR 20, 1994
AB + 160MG N19865 002 OCT 30, 1992
AB 240MG N19865 003 OCT 30, 1992
80MG N19865 001 OCT 30, 1992
120MG N19865 005 APR 20, 1994
+ 160MG N19865 002 OCT 30, 1992
240MG N19865 003 OCT 30, 1992
BETAPACE AF
BERLEX LABS 80MG N21151 001 FEB 22, 2000
120MG N21151 002 FEB 22, 2000
+ 160MG N21151 003 FEB 22, 2000
SOTALOL HCL
AB EON 80MG N75366 001 MAY 01, 2000
AB 120MG N75366 002 MAY 01, 2000
AB 160MG N75366 003 MAY 01, 2000
AB 240MG N75366 004 MAY 01, 2000
AB GENPHARM 80MG N75237 001 MAY 01, 2000
AB 120MG N75237 002 MAY 01, 2000
AB 160MG N75237 003 MAY 01, 2000
AB 240MG N75237 004 MAY 01, 2000
AB TEVA 80MG N75429 001 MAY 01, 2000
AB 120MG N75429 002 MAY 01, 2000

SOTALOL HYDROCHLORIDE

TABLET; ORAL
SOTALOL HCL

	AB	TEVA	160MG	N75429 003	
	AB		240MG	MAY 01, 2000	> DLT >
> ADD >	AB	WATSON LABS	80MG	N75429 004	> DLT >
> ADD >				MAY 01, 2000	> DLT >
> ADD >	AB		120MG	N75238 001	> DLT >
> ADD >				JUL 13, 2000	> DLT >
> ADD >	AB		160MG	N75238 002	
> ADD >				JUL 13, 2000	
> ADD >	AB		240MG	N75238 003	
> ADD >				JUL 13, 2000	
				N75238 004	
				JUL 13, 2000	

SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC
OCUSULF-10

> ADD >	AT	MIZA PHARMS USA	10%	N80660 001
> DLT >	AT	OPTOPICS	10%	N80660 001
		OCUSULF-30		
> ADD >		@ MIZA PHARMS USA	30%	N80660 002
> DLT >		@ OPTOPICS	30%	N80660 002
		SULFACETAMIDE SODIUM		
	AT	ALCON UNIVERSAL	10%	N89560 001
				OCT 18, 1988
	AT	STERIS	10%	N89560 001
				OCT 18, 1988

TACRINE HYDROCHLORIDE

CAPSULE; ORAL
COGNEX

> ADD >		FIRST HORIZON	EQ 10MG BASE	N20070 001
> ADD >				SEP 09, 1993
> ADD >			EQ 20MG BASE	N20070 002
> ADD >				SEP 09, 1993
> ADD >			EQ 30MG BASE	N20070 003
> ADD >				SEP 09, 1993
> ADD >	+		EQ 40MG BASE	N20070 004
> ADD >				SEP 09, 1993
> DLT >		PARKE DAVIS PHARMS	EQ 10MG BASE	N20070 001
> DLT >				SEP 09, 1993

TACRINE HYDROCHLORIDE

CAPSULE; ORAL
COGNEX

		PARKE DAVIS PHARMS	EQ 20MG BASE	N20070 002
				SEP 09, 1993
			EQ 30MG BASE	N20070 003
				SEP 09, 1993
	*		EQ 40MG BASE	N20070 004
				SEP 09, 1993

TAMOXIFEN CITRATE

TABLET; ORAL
TAMOXIFEN CITRATE

@ MYLAN	EQ 10MG BASE	N74732 001
		JUN 26, 2000
@ PHARMACHEMIE	EQ 10MG BASE	N74539 001
		MAY 31, 2000

TELMISARTAN

TABLET; ORAL
MICARDIS
+ BOEHRINGER INGELHEIM 20MG N20850 003
APR 04, 2000

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL
TERAZOSIN HCL

> ADD >	AB	INVAMED	EQ 1MG BASE	N75667 001
> ADD >				JUL 28, 2000
> ADD >	AB		EQ 2MG BASE	N75667 002
> ADD >				JUL 28, 2000
> ADD >	AB		EQ 5MG BASE	N75667 003
> ADD >				JUL 28, 2000
> ADD >	AB		EQ 10MG BASE	N75667 004
> ADD >				JUL 28, 2000
	AB	MYLAN	EQ 1MG BASE	N75140 002
				FEB 11, 2000
	AB		EQ 2MG BASE	N75140 003
				FEB 11, 2000
	AB		EQ 5MG BASE	N75140 001
				FEB 11, 2000

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL
TERAZOSIN HCL

AB	MYLAN	EQ 10MG BASE	N75140 004	FEB 11, 2000

TABLET; ORAL
TERAZOSIN HCL

AB	INVAMED	EQ 1MG BASE	N74657 001	APR 28, 2000
AB		EQ 2MG BASE	N74657 002	APR 28, 2000
AB		EQ 5MG BASE	N74657 003	APR 28, 2000
AB		EQ 10MG BASE	N74657 004	APR 28, 2000
AB	NOVOPHARM	EQ 1MG BASE	N74446 001	MAY 18, 2000
AB		EQ 2MG BASE	N74446 002	MAY 18, 2000
AB		EQ 5MG BASE	N74446 003	MAY 18, 2000
AB		EQ 10MG BASE	N74446 004	MAY 18, 2000
AB	ZENITH GOLDLINE	EQ 1MG BASE	N74530 001	APR 21, 2000
AB		EQ 2MG BASE	N74530 002	APR 21, 2000
AB		EQ 5MG BASE	N74530 003	APR 21, 2000
AB		EQ 10MG BASE	N74530 004	APR 21, 2000

TESTOSTERONE

FILM, EXTENDED RELEASE; TRANSDERMAL
ANDRODERM

BX	+ THERATECH	5MG/24HR	N20489 002	MAY 02, 1997
	+	2.5MG/24HR	N20489 001	SEP 29, 1995
BX	+ WATSON LABS	5MG/24HR	N20489 002	MAY 02, 1997
	+	2.5MG/24HR	N20489 001	SEP 29, 1995

TESTOSTERONE

GEL; TOPICAL
ANDROGEL

	+ UNIMED PHARMS	1%	N21015 001	FEB 28, 2000

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL
SLO-PHYLLIN

	@ AVENTIS PHARM PROD	60MG	N85206 001	MAY 24, 1982
	@	125MG	N85203 001	MAY 24, 1982
	@	250MG	N85205 001	MAY 24, 1982
BC	RHONE POULENC RORER	125MG	N85203 001	MAY 24, 1982
BC		250MG	N85205 001	MAY 24, 1982
		60MG	N85206 001	MAY 24, 1982

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
BETALIN S

AP	+ LILLY	100MG/ML	N80853 001	
	@	100MG/ML	N80853 001	

THIAMINE HCL

AP	AM PHARM PARTNERS	100MG/ML	N80556 001	
AP	+	100MG/ML	N80556 001	

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL
TICLOPIDINE HCL

AB	DANBURY PHARMA	250MG	N75309 001	APR 26, 2000

> ADD > TINZAPARIN SODIUM

> ADD > INJECTABLE; INJECTION
> ADD > INNOHEP
> ADD > + DUPONT PHARMA 20,000 IU/ML N20484 001 JUL 14, 2000
> ADD >

TOLBUTAMIDE

TABLET; ORAL
TOLBUTAMIDE
AB CHELSEA LABS 500MG N86109 001
AB + 500MG N86109 001
AB * EON 500MG N12678 001
@ 500MG N12678 001

TRETINOIN

GEL; TOPICAL
RETIN-A
AB + JOHNSON AND JOHNSON 0.025% N17579 002
BT * 0.025% N17579 002
TRETINOIN
AB SPEAR PHARMS 0.025% N75529 001 FEB 22, 2000

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL
> DLT > FLUTEX
> DLT > AT ZENITH GOLDLINE 0.025% N85539 001
> DLT > AT 0.1% N85539 002
> DLT > AT 0.5% N85539 003
> ADD > @ 0.025% N85539 001
> ADD > @ 0.1% N85539 002
> ADD > @ 0.5% N85539 003
> DLT > TRIATEX
> DLT > AT ZENITH GOLDLINE 0.025% N87430 001 NOV 01, 1988
> DLT > N87429 001
> DLT > AT 0.1% NOV 01, 1988
> DLT > N87428 001
> DLT > AT 0.5% NOV 01, 1988
> DLT > N87430 001
> ADD > @ 0.025% NOV 01, 1988
> ADD >

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL
> ADD > TRIATEX
> ADD > @ ZENITH GOLDLINE 0.1% N87429 001 NOV 01, 1988
> ADD >
> ADD > @ 0.5% N87428 001 NOV 01, 1988
> ADD >

OINTMENT; TOPICAL
ARISTOCORT A
AT * FUJISAWA HLTHCARE 0.5% N80745 003
AT 0.5% N80745 003
> DLT > FLUTEX
> DLT > AT * ZENITH GOLDLINE 0.025% N87375 001 NOV 01, 1988
> DLT > AT * 0.1% N87377 001 NOV 01, 1988
> DLT > AT * 0.5% N87376 001 NOV 01, 1988
> DLT > N87375 001
> ADD > @ 0.025% NOV 01, 1988
> ADD > N87377 001
> ADD > @ 0.1% NOV 01, 1988
> ADD > N87376 001
> ADD > @ 0.5% NOV 01, 1988
> ADD >
KENALOG
AT * APOTHECON 0.025% N11600 003
AT 0.025% N11600 003
AT * 0.1% N11600 001
AT 0.1% N11600 001
TRIAMCINOLONE ACETONIDE
> DLT > ALTANA
> ADD > AT + 0.025% N85691 001
> DLT > AT 0.025% N85691 001
> ADD > AT + 0.1% N85691 003
> DLT > AT 0.1% N85691 003
> ADD > AT + 0.5% N85691 002
AT 0.5% N85691 002

SPRAY, METERED; NASAL
TRI-NASAL
+ MURO 0.05MG/SPRAY N20120 001 FEB 04, 2000

TRIFLUOPERAZINE HYDROCHLORIDE

TABLET; ORAL
TRIFLUOPERAZINE HCL

> DLT >	AB	ZENITH GOLDLINE	EQ 1MG BASE	N87612 001 NOV 19, 1982
> DLT >	AB		EQ 2MG BASE	N87613 001 NOV 19, 1982
> DLT >	AB		EQ 5MG BASE	N87328 001 NOV 19, 1982
> DLT >	AB		EQ 10MG BASE	N87614 001 NOV 19, 1982
> ADD >	@		EQ 1MG BASE	N87612 001 NOV 19, 1982
> ADD >	@		EQ 2MG BASE	N87613 001 NOV 19, 1982
> ADD >	@		EQ 5MG BASE	N87328 001 NOV 19, 1982
> ADD >	@		EQ 10MG BASE	N87614 001 NOV 19, 1982

TRIHEXYPHENIDYL HYDROCHLORIDE

TABLET; ORAL
TRIHEXYPHENIDYL HCL

AA		WEST WARD	2MG	N40337 002 FEB 16, 2000
AA			5MG	N40337 001 FEB 16, 2000

TRIMETHOPRIM HYDROCHLORIDE

SOLUTION; ORAL
PRIMSOL

		ASCENT PEDS	EQ 25MG BASE/5ML	N74374 001 JUN 23, 1995
	+		EQ 25MG BASE/5ML	N74374 001 JUN 23, 1995
	+		EQ 50MG BASE/5ML	N74973 001 JAN 24, 2000

TRIMETREXATE GLUCURONATE

INJECTABLE; INJECTION
NEUTREXIN

	+	MEDIMMUNE ONCOLOGY	EQ 25MG BASE/VIAL	N20326 001 DEC 17, 1993

TRIMETREXATE GLUCURONATE

INJECTABLE; INJECTION
NEUTREXIN

	*	US BIOSCIENCE	EQ 25MG BASE/VIAL	N20326 001 DEC 17, 1993

TRIPTORELIN PAMOATE

INJECTABLE; INJECTION
TRELSTAR DEPOT

	+	DEBIO RECHERCHE	EQ 3.75MG BASE/VIAL	N20715 001 JUN 15, 2000

TROGLITAZONE

TABLET; ORAL
PRELAY

AB		SANKYO	200MG	N20719 001 JAN 29, 1997
AB			300MG	N20719 003 AUG 04, 1997
AB			400MG	N20719 002 JAN 29, 1997
	@		200MG	N20719 001 JAN 29, 1997
	@		300MG	N20719 003 AUG 04, 1997
	@		400MG	N20719 002 JAN 29, 1997

REZULIN

AB		PARKE DAVIS PHARMS	200MG	N20720 001 JAN 29, 1997
AB			300MG	N20720 003 AUG 04, 1997
AB			400MG	N20720 002 JAN 29, 1997
	@		200MG	N20720 001 JAN 29, 1997
	@		300MG	N20720 003 AUG 04, 1997
	@		400MG	N20720 002 JAN 29, 1997

TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC

		TROPICAMIDE			
	AT	ALCON UNIVERSAL	**1%**		**N89172 001** DEC 28, 1990
> ADD >	**AT**	MIZA PHARMS USA	**0.5%**		**N87636 001** JUL 30, 1982
> ADD >					**N87637 001** AUG 09, 1982
> ADD >	**AT**		**1%**		
> DLT >	**AT**	OPTOPICS	**0.5%**		**N87636 001** JUL 30, 1982
> DLT >					**N87637 001** AUG 09, 1982
> DLT >	**AT**		**1%**		
> DLT >	**AT**	STERIS	**1%**		**N89172 001** DEC 28, 1990

URSODIOL

CAPSULE; ORAL

		ACTIGALL			
AB	+	NOVARTIS	**300MG**		**N19594 002** DEC 31, 1987
	*		**300MG**		**N19594 002** DEC 31, 1987
		URSODIOL			
AB		AMIDE PHARM	**300MG**		**N75517 001** MAR 14, 2000
AB		COPLEY PHARM	**300MG**		**N75592 001** MAY 25, 2000

TABLET; ORAL

		URSO			
	*	AXCAN	**250MG**		**N20675 001** DEC 10, 1997
	+	AXCAN SCANDIPHARM	250MG		N20675 001 DEC 10, 1997

VECURONIUM BROMIDE

INJECTABLE; INJECTION

		VECURONIUM BROMIDE			
AP		BEDFORD	**10MG/VIAL**		**N75549 001** JUN 13, 2000
AP			**20MG/VIAL**		**N75549 002** JUN 13, 2000

VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

		COVERA-HS			
BC		SEARLE	**180MG**		**N20552 001** FEB 26, 1996
BC	+		180MG		N20552 001 FEB 26, 1996
BC			**240MG**		**N20552 002** FEB 26, 1996
BC	+		240MG		N20552 002 FEB 26, 1996

VERTEPORFIN

INJECTABLE; INJECTION

		VISUDYNE			
	+	QLT	15MG/VIAL		N21119 001 APR 12, 2000

VITAMIN A

CAPSULE; ORAL

		VITAMIN A			
AA		GLOBAL PHARM	**50,000 USP UNITS**		**N80952 001**
	@	IMPAX LABS	50,000 USP UNITS		N80952 001

VITAMIN A PALMITATE

CAPSULE; ORAL

		VITAMIN A			
AA		GLOBAL PHARM	**EQ 50,000 UNITS BASE**		**N80953 001**
AA			**EQ 50,000 UNITS BASE**		**N80955 001**
	@	IMPAX LABS	EQ 50,000 UNITS BASE		N80953 001
	@		EQ 50,000 UNITS BASE		N80955 001

WARFARIN SODIUM

TABLET; ORAL

		WARFARIN SODIUM			
AB		INVAMED	**3MG**	> ADD >	**N40196 008** JUL 26, 2000
				> ADD >	
AB			**6MG**	> ADD >	**N40196 009** JUL 26, 2000
				> ADD >	

ZOLMITRIPTAN

TABLET; ORAL			
ZOMIG			
IPR	2.5MG	N20768 001	
		NOV 25, 1997	
+	5MG	N20768 002	
		NOV 25, 1997	
ZENECA	2.5MG	N20768 001	
		NOV 25, 1997	
*	5MG	N20768 002	
		NOV 25, 1997	

ZONISAMIDE

CAPSULE; ORAL			
ZONEGRAN			
+ DAINIPPON	100MG	N20789 001	
		MAR 27, 2000	

OTC DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 7 / JAN'2000 - JUL'2000

ACETAMINOPHEN

TABLET, EXTENDED RELEASE; ORAL

ACETAMINOPHEN		
PERRIGO	650MG	N75077 001 FEB 25, 2000

ASPIRIN

TABLET, EXTENDED RELEASE; ORAL

8-HOUR BAYER		
* BAYER	650MG	N16030 001
@	650MG	N16030 001
MEASURIN		
* BAYER	650MG	N16030 002
@	650MG	N16030 002

BROMPHENIRAMINE MALEATE

> ADD > TABLET, EXTENDED RELEASE; ORAL

> ADD > DIMETANE		
> ADD > @ WHITEHALL ROBINS	12MG	N10799 011 JUN 10, 1983
> ADD >		
> DLT > DIMETAPP		
> DLT > * WHITEHALL ROBINS	12MG	N10799 011 JUN 10, 1983
> DLT >		

CHLORHEXIDINE GLUCONATE

SPONGE; TOPICAL

E-Z SCRUB		
BECTON DICKINSON	4%	N73416 001 MAR 14, 2000

> ADD > CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

> ADD > SOLUTION; TOPICAL

> ADD > CHLORAPREP		
> ADD > + MEDI FLEX HOSP	2%;70%	N20832 001 JUL 14, 2000
> ADD >		

CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CONTAC		
@ SMITHKLINE	8MG;75MG	N18099 001
+	8MG;75MG	N18099 001

CIMETIDINE

TABLET; ORAL

CIMETIDINE		
LEINER	200MG	N74961 001 JUN 19, 1998
NOVOPHARM	200MG	N74961 001 JUN 19, 1998

CLOTRIMAZOLE

CREAM; VAGINAL

TRIVAGIZOLE 3		
+ TARO	2%	N21143 001 APR 12, 2000

> ADD > DOCOSANOL

> ADD > CREAM; TOPICAL

> ADD > ABREVA		
> ADD > + AVANIR	10%	N20941 001 JUL 25, 2000
> ADD >		

IBUPROFEN

CAPSULE; ORAL

IBUPROFEN		
PHARM FORM	200MG	N74782 001 JUL 06, 1998
+	200MG	N74782 001 JUL 06, 1998

TABLET; ORAL

IBUPROFEN		
LEINER	200MG	N74931 001 JUL 20, 1998
NOVOPHARM	200MG	N74931 001 JUL 20, 1998

LOPERAMIDE HYDROCHLORIDE

TABLET; ORAL
LOPERAMIDE HCL

LEINER	2MG	N73254 001 JUL 30, 1993
NOVOPHARM NC	2MG	N73254 001 JUL 30, 1993
PERRIGO	2MG	N75232 001 JAN 06, 2000

NAPROXEN SODIUM

TABLET; ORAL
NAPROXEN SODIUM

LEINER	EQ 200MG BASE	N74635 001 JAN 13, 1997
NOVOPHARM NC	EQ 200MG BASE	N74635 001 JAN 13, 1997

PERMETHRIN

LOTION; TOPICAL
PERMETHRIN

ALPHARMA	1%	N75014 001 MAR 28, 2000

PIPERONYL BUTOXIDE; PYRETHRINS

AEROSOL; TOPICAL
RID MOUSSE

+ PFIZER	4%;EQ 0.33% BASE	N21043 001 MAR 07, 2000

RANITIDINE HYDROCHLORIDE

TABLET; ORAL
RANITIDINE

CHELSEA LABS	EQ 75MG BASE	N75212 001 JAN 14, 2000
CHEMINOR DRUGS	EQ 75MG BASE	N75294 001 MAR 28, 2000
GENPHARM	EQ 75MG BASE	N75497 001 JAN 14, 2000

RANITIDINE HYDROCHLORIDE

TABLET; ORAL
RANITIDINE

LEINER	EQ 75MG BASE	N75094 001 JUN 21, 1999
RANBAXY	EQ 75MG BASE	N75132 001 JAN 14, 2000
	EQ 75MG BASE	N75254 001 JAN 14, 2000
TORPHARM	EQ 75MG BASE	N75167 001 MAY 04, 2000
ZENITH GOLDLINE	EQ 75MG BASE	N75296 001 JAN 14, 2000

RANITIDINE HCL

NOVOPHARM	EQ 75MG BASE	N75094 001 JUN 21, 1999

TABLET, EFFERVESCENT; ORAL
ZANTAC 75

* GLAXO WELLCOME	EQ 75MG BASE	N20745 001 FEB 26, 1998
@ WARNER LAMBERT	EQ 75MG BASE	N20745 001 FEB 26, 1998

TERBINAFINE HYDROCHLORIDE

SOLUTION; TOPICAL
LAMISIL AT

+ NOVARTIS	1%	N21124 001 MAR 17, 2000

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 7 JULY '00

NO JULY 2000 APPROVALS

This data is provided to the Division of Data Management and Services from the Office of Orphan Products Development and it is not edited prior to publication.

Orphan Products Designations and Approvals List
January through July 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
1-(11-dodecylamino-10-hydroxyundecyl)-3,7-dimethylxanthine hydrogen methanesulfonate TN=	Treatment of hormone refractory prostate carcinoma.	Cell Therapeutics, Inc. 201 Elliott Avenue West Suite 400 Seattle WA 98119 DD= 1/18/00 MA=
3-(3,5-Dimethyl-1H-2ylmethylene)-1,3-dihydro-indol-2-one TN=	Treatment of von Hippel-Lindau disease.	Sugen, Inc. 230 East Grand Ave. South San Francisco CA 94080 DD= 3/23/00 MA=
Abetimus TN=	Treatment of lupus nephritis.	La Jolla Pharmaceutical Co. 6455 Nancy Ridge Dr. San Diego CA 92121 DD= 7/28/00 MA=
Angiotensin 1-7 TN=	Treatment of neutropenia associated with autologous bone marrow transplantation.	Maret Pharmaceuticals 4041 MacArthur Blvd. Suite 375 Newport Beach CA 92660 DD= 2/16/00 MA=
Arsenic trioxide TN=Atrivex	Treatment of multiple myeloma.	Cell Therapeutics, Inc. 201 Elliott Ave. West, Suite Seattle WA 98119 DD= 4/28/00 MA=

Orphan Products Designations and Approvals List
January through July, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Bis(4-fluorophenyl)phenyla cetamide TN=	Treatment of sickle cell disease.	ICAgen Inc. Ion Channel Advances PO Box 14487 Durham NC 27709 DD= 3/2/00 MA=
Brimonidine TN=Alphagan	Treatment of anterior ischemic optic neuropathy.	Allergan, Inc. 2525 Dupont Dr. P.O. Box 19534 Irvine CA 92623-9534 DD= 2/7/00 MA=
Carmustine TN=	Treatment of intracranial malignancies.	Direct Therapeutics, Inc. 1001 Bayhill Dr., Suite 100 San Bruno CA 94066 DD= 7/3/00 MA=
Centruroides immune F(ab)2 TN=Alacramyn	Treatment of scorpion envenomations requiring medical attention.	Silanes Laboratories S.A. de Amores #1034 Col Del Valle C.P. 03100 Mexico D.F. DD= 6/12/00 MA=
Cetuximab TN=	Treatment of squamous cell cancer of the head and neck in patients who express epidermal growth factor receptor.	ImClone Systems Incorporated Branchburg Corporate Center 22 Chubb Way Somerville NJ 08876 DD= 7/3/00 MA=

Orphan Products Designations and Approvals List
January through July, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Cisplatin/epinephrine	Treatment of squamous cell carcinoma of the head and neck.	Matrix Pharmaceutical, Inc. 34700 Campus Drive Fremont CA 94555-3612
TN= IntraDose		DD= 4/3/00 MA=
Deoxyribose, phosphorothioate	Treatment of advanced malignant melanoma (Stages II,III, IV).	Genta, Inc. 99 Hayden Ave., Suite 200 Lexington MA 02421-7966
TN=		DD= 7/31/00 MA=
DNA-lipid complex (DMRIE/DOPE)/plasmid vector (VCL-1102, Vical) expressing human interleukin-2	Treatment of renal cell carcinoma.	Vical Incorporated 9373 Towne Center Dr. Suite 100 San Diego CA 92121-3088
TN= Leuvectin		DD= 4/28/00 MA=
Ethyl eicosapentaenoate	Treatment of Huntington's disease.	Laxdale Ltd. Kings Park House, Laurelhill Polmaise Road, Stirling FK7 United Kingdom UK
TN=		DD= 4/6/00 MA=
Flucinolone	Treatment uveitis involving the posterior segment of the eye.	Bausch & Lomb 8500 Hidden River Parkway Tampa FL 33637
TN=		DD= 7/31/00 MA=

Orphan Products Designations and Approvals List
January through July, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Fluorouracil TN=	Treatment of glioblastoma multiforme.	Ethypharm SA 194 Bureaux de la Colline - 92213 Saint-Cloud Cedex France FR DD= 6/29/00 MA=
Halofuginone TN= Stenorol	Treatment of systemic sclerosis.	Collgard Biopharmaceuticals Tekstile House, 2 Koifman St. Tel-Aviv 68012 Israel IL DD= 2/7/00 MA=
Histamine TN= Maxamine	For use as an adjunct to cytokine therapy in the treatment of malignant melanoma.	Maxim Pharmaceuticals, Inc. 8899 University Center Lane Suite 400 San Diego CA 92122 DD= 2/1/00 MA=
Hypericin TN=	Treatment of cutaneous T-cell lymphoma.	Nexell Therapeutics, Inc. 2751 Centerville Rd., Suite Wilmington DE 19808 DD= 2/7/00 MA=
IL-4 Pseudomonas Toxin Fusion Protein (IL-4(38-37)-PE38KDEL) TN=	Treatment of astrocytic glioma.	Neurocrine Biosciences, Inc. 10555 Science Center Dr. San Diego CA 92121 DD= 4/6/00 MA=

Orphan Products Designations and Approvals List
January through July, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Iodine I 131 bis(indium-diethylenetriaminepentaacetic acid)tyrosyllysine/hMN-14 x m734 F(ab')2 bispecific monoclonal antibody TN=Pentacea	Treatment of small-cell lung cancer.	IBC Pharmaceuticals, L.L.C. 300 American Rd. Morris Plains NJ 07950 DD= 2/22/00 MA=
Levodopa and carbidopa TN=Duodopa	Treatment of late stage Parkinson's disease.	Nouvel Pharma, Inc. 11322 Acuff La. Lenexa KS 66215 DD= 1/18/00 MA=
Liposomal nystatin TN=Nyotran	Treatment of invasive fungal infections.	Aronex Pharmaceuticals, Inc. 8707 Technology Forest Place The Woodlands TX 77381-1191 DD= 6/13/00 MA=
Meropenem TN=Merrem IV	Management of acute pulmonary exacerbations, in cystic fibrosis patients, due to respiratory tract infection with susceptible organisms.	Zeneca Pharmaceuticals 1800 Concord Pike PO Box 15437 Wilmington DE 19850-5437 DD= 4/27/00 MA=
Natural human lymphoblastoid interferon-alpha TN=	Treatment of Behcet's disease.	Amarillo Biosciences, Inc. 800 West Ninth Avenue Amarillo TX 79101-3206 DD= 1/18/00 MA=

Orphan Products Designations and Approvals List
January through July, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Omega-3 (n-3) polyunsaturated fatty acids TN= Omacor	Treatment of IgA nephropathy.	Pronova Biocare, AS PO Box 420 1327 Lysaker Norway DD= 5/4/00 MA=
Phenylbutyrate TN=	Treatment of acute promyelocytic leukemia.	Elan Corporation 1300 Gould Dr. Gainesville GA 30504 DD= 1/19/00 MA=
Recombinant glycine2-human glucagon-like peptide-2 TN=	Treatment of short bowel syndrome.	NPS Allelix Corp. 6850 Goreway Dr. Mississauga, Ontario L4V 1V7 Canada CA DD= 6/29/00 MA=
Recombinant human antithrombin III TN=	Treatment of antithrombin III dependent heparin resistance requiring anticoagulation.	AT III LLC c/o Genzyme Corporation 15 Pleasant St. Connector, Framingham MA 01701 DD= 4/6/00 MA=
Recombinant human insulin-like growth factor-I TN= PV802	Treatment of short-bowel syndrome as a result of resection of the small bowel or as a result of congenital dysfunction of the intestines.	GroPep Pty Ltd. Gate 11, Victoria Dr. Adelaide SA 5000 Australia AU DD= 2/16/00 MA=

Orphan Products Designations and Approvals List
January through July, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Remacemide TN= Ecovia	Treatment of Huntington's disease.	AstraZeneca LP 725 Chesterbrook Blvd. Wayne PA 19087-5677 DD= 3/6/00 MA=
rSP-C lung surfactant TN= Venticute	Treatment of adult respiratory distress syndrome.	Byk Gulden Pharmaceuticals Byk-Gulden StraBe 2 78467 Konstanz Germany DE DD= 4/3/00 MA=
Soluble complement receptor type 1 TN=	Prevention of post-cardiopulmonary bypass syndrome in children undergoing cardiopulmonary bypass.	Avant Immunotherapeutics, 119 Fourth Ave. Needham MA 02494-2725 DD= 3/6/00 MA=
Synthetic human secretin TN=	For use in conjunction with diagnostic procedures for pancreatic disorders to increase pancreatic fluid secretion.	ChiRhoClin, Inc. 15500 Gallaudet Ave. Silver Spring MD 20905-4176 DD= 3/7/00 MA=
Synthetic porcine secretin TN=	For use in conjunction with diagnostic procedures for pancreatic disorders to increase pancreatic fluid secretion.	ChiRhoClin, Inc. 15500 Gallaudet Ave. Silver Spring MD 20905-4176 DD= 3/7/00 MA=

Orphan Products Designations and Approvals List
January through July, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Technetium Tc 99m pterotetramide TN=	For the identification of ovarian carcinomas.	Endocyte, Inc. 1205 Kent Ave. Lafayette IN 47906 DD= 2/16/00 MA=
Tetraiodothyroacetic acid TN=	Suppression of thyroid stimulating hormone in patients with well-differentiated cancer of the thyroid gland.	Danforth, Jr., MD, Elliot University of Vermont 84 Beartown Rd. Underhill VT 05489 DD= 5/1/00 MA=
Thymalfasin TN= Zadaxin	Treatment of hepatocellular carcinoma.	SciClone Pharmaceuticals, 901 Mariner's Blvd., Suite San Mateo CA 94404 DD= 3/6/00 MA=
Vapreotide TN= Octastatin	Treatment of gastrointestinal and pancreatic fistulas.	Debiopharm S.A. 17 rue des Terreaux CH-1000 Lausanne 9 Switzerland CH DD= 1/10/00 MA=
Vapreotide TN= Octastatin	Prevention of early postoperative complications following pancreatic resection.	Debiopharm S.A. 17 rue des Terreaux CH-1000 Lausanne 9 Switzerland CH DD= 3/6/00 MA=

Orphan Products Designations and Approvals List
January through July, 2000

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Vapreotide	Treatment of esophageal variceal hemorrhage patients with portal hypertension.	Debiopharm S.A. 17 rue des Terreaux CH-1000 Lausanne 9 Switzerland CH DD= 1/10/00 MA=
TN=Octastatin		
vigabatrin	Treatment of infantile spasms.	Aventis Pharmaceuticals Inc. P.O. Box 9627 Kansas City MO 64137 DD= 6/12/00 MA=
TN=Sabril		

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO JULY 2000 ADDITIONS

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	075077 001	ACETAMINOPHEN;ACETAMINOPHEN				PC	NOV 12, 2000
>ADD>	020338 001	ADAPALENE;DIFFERIN	4717720	MAY 31, 2010			
>ADD>	020380 001	ADAPALENE;DIFFERIN	4717720	MAY 31, 2010			
>ADD>	020748 001	ADAPALENE;DIFFERIN	4717720	MAY 31, 2010		NCE	MAY 31, 2001
>ADD>			RE34440	MAY 31, 2010	U-275	NDF	MAY 26, 2003
	020760 001	ALATROFLOXACIN MESYLATE;TROVAN PRESERVATIVE	6080756	JUL 05, 2016			
	020760 002	ALATROFLOXACIN MESYLATE;TROVAN PRESERVATIVE	6080756	JUL 05, 2016			
>ADD>	020560 001	ALENDRONATE SODIUM;FOSAMAX	6090410	DEC 02, 2012		M-3	NOV 24, 2002
			6008207	JUN 06, 2015	U-303		
>ADD>	020560 002	ALENDRONATE SODIUM;FOSAMAX	6090410	DEC 02, 2012		M-3	NOV 24, 2002
			6008207	JUN 06, 2015	U-303		
>ADD>	020560 003	ALENDRONATE SODIUM;FOSAMAX	6090410	DEC 02, 2012		M-3	NOV 24, 2002
			6008207	JUN 06, 2015	U-303		
	021107 001	ALOSETRON HYDROCHLORIDE;LOTRONEX				NCE	FEB 09, 2005
	020221 001	AMIFOSTINE;ETHYOL				I-283	JUN 24, 2002
	020221 002	AMIFOSTINE;ETHYOL				I-283	JUN 24, 2002
	021007 001	AMPRENAVIR;AGENERASE	5723490	MAR 03, 2013	U-257		
			5646180	JUL 08, 2014	U-257		
			5585397	DEC 17, 2013			
	021007 002	AMPRENAVIR;AGENERASE	5723490	MAR 03, 2015	U-257		
			5646180	JUL 08, 2014	U-257		
			5585397	DEC 17, 2013			
	021039 001	AMPRENAVIR;AGENERASE	5723490	MAR 03, 2015	U-257		
			5646180	JUL 08, 2014	U-257		
	020541 001	ANASTROZOLE;ARIMIDEX	RE36617	DEC 27, 2009			
	020883 001	ARGATROBAN;ACOVA				NCE	JUN 30, 2005
	020971 001	ARTICAINE HYDROCHLORIDE;SEPTOCAINE				NC	APR 03, 2003
	021127 001	AZELASTINE HYDROCHLORIDE;OPTIVAR	5164194	NOV 01, 2010		NCE	NOV 01, 2001
			5164194*	MAY 01, 2011		NDF	MAY 22, 2003
						PED	MAY 01, 2002
						PED	NOV 22, 2003
>ADD>	020610 001	BALSALAZIDE DISODIUM;COLAZAL	4412992	JUL 08, 2001		NCE	JUL 18, 2005
	021055 001	BEXAROTENE;TARGRETIN				ODE	DEC 29, 2006
	021056 001	BEXAROTENE;TARGRETIN				NCE	DEC 29, 2004
	019982 001	BISOPROLOL FUMARATE;ZEBETA	4258062	MAR 24, 2000	U-63		
			4258062*PED	SEP 24, 2000	U-63		
	019982 002	BISOPROLOL FUMARATE;ZEBETA	4258062	MAR 24, 2000	U-63		
			4258062*PED	SEP 24, 2000	U-63		
	020186 001	BISOPROLOL FUMARATE;ZIAC	4258062	MAR 24, 2000	U-63		
			4258062*PED	SEP 24, 2000	U-63		
	020186 002	BISOPROLOL FUMARATE;ZIAC	4258062	MAR 24, 2000	U-63		
			4258062*PED	SEP 24, 2000	U-63		
	020186 003	BISOPROLOL FUMARATE;ZIAC	4258062	MAR 24, 2000	U-63		
			4358062*PED	SEP 24, 2000	U-63		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	050443 002	BLEOMYCIN SULFATE;BLENOXANE				ODE	FEB 20, 2003
>ADD>	020929 001	BUDESONIDE;PULMICORT RESPULES	4787536	FEB 27, 2006		NDF	AUG 08, 2003
>ADD>	020929 002	BUDESONIDE;PULMICORT RESPULES	4787536	FEB 27, 2006		NDF	AUG 08, 2003
	020711 002	BUPROPION HYDROCHLORIDE;ZYBAN				D-54	SEP 10, 2002
	020711 003	BUPROPION HYDROCHLORIDE;ZYBAN				D-54	SEP 10, 2002
	018731 001	BUSPIRONE HYDROCHLORIDE;BUSPAR	4182763	MAY 22, 2000	U-13		
			5015646	MAY 14, 2008			
			4182763*PED	NOV 22, 2000	U-13		
			5015646*PED	NOV 14, 2008			
	018731 002	BUSPIRONE HYDROCHLORIDE;BUSPAR	4182763	MAY 22, 2000	U-13		
			5015646	MAY 14, 2008			
			4182763*PED	NOV 22, 2000	U-13		
			5015646*PED	NOV 14, 2008			
	018731 003	BUSPIRONE HYDROCHLORIDE;BUSPAR	5015646	MAY 14, 2008			
			4182763	MAY 22, 2000	U-13		
			4182763*PED	NOV 22, 2000	U-13		
			5015646*PED	NOV 14, 2008			
	018731 004	BUSPIRONE HYDROCHLORIDE;BUSPAR	4182763	MAY 22, 2000	U-13		
			5015646	MAY 14, 2008			
			4182763*PED	NOV 22, 2000			
			5015646*PED	NOV 14, 2008	U-13		
	020793 001	CAFFEINE CITRATE;CAFCIT				ODE	SEP 21, 2006
	018874 001	CALCITRIOL;CALCIJEX	6051567	AUG 02, 2019			
	018874 002	CALCITRIOL;CALCIJEX	6051567	AUG 02, 2019			
>ADD>	020896 001	CAPECITABINE;XELODA	4966891	JAN 13, 2011	U-272		
>ADD>	020896 002	CAPECITABINE;XELODA	4966891	JAN 13, 2011	U-272		
	020297 001	CARVEDILOL;COREG	5902821	FEB 07, 2016	U-313		
	020297 002	CARVEDILOL;COREG	5902821	FEB 07, 2016	U-313		
	020297 003	CARVEDILOL;COREG	5902821	FEB 07, 2016	U-313		
	020297 004	CARVEDILOL;COREG	5902821	FEB 07, 2016	U-313		
	020740 001	CERIVASTATIN SODIUM;BAYCOL				D-59	JUL 21, 2003
						I-303	JUL 21, 2003
	020740 002	CERIVASTATIN SODIUM;BAYCOL				D-59	JUL 21, 2003
						I-303	JUL 21, 2003
	020740 003	CERIVASTATIN SODIUM;BAYCOL				D-59	JUL 21, 2003
						I-303	JUL 21, 2003
	020740 004	CERIVASTATIN SODIUM;BAYCOL				D-59	JUL 21, 2003
						I-303	JUL 21, 2003
	020740 005	CERIVASTATIN SODIUM;BAYCOL				D-59	JUL 21, 2003
						I-303	JUL 21, 2003
>ADD>	020740 006	CERIVASTATIN SODIUM;BAYCOL	5006530	JAN 17, 2009		D-59	JUL 21, 2003
>ADD>			5177080	JAN 26, 2011		I-303	JUL 21, 2003
						NS	JUL 21, 2003
	020989 002	CEVIMELINE HYDROCHLORIDE;EVOXAC	4855290	AUG 08, 2006		NCE	JAN 11, 2005
			5340821	AUG 23, 2011	U-309		
			5580880	JUN 06, 2015	U-310		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020832 001	CHLORHEXIDINE GLUCONATE;CHLORAPREP				NC	JUL 14, 2003
	021142 001	CLOBETASOL PROPIONATE;OLUX FOAM				NDF	MAY 26, 2003
	021143 001	CLOTRIMAZOLE;TRIVAGIZOLE 3				NP	NOV 24, 2001
	021141 001	COLESEVELAM HYDROCHLORIDE;WELCHOL	5624963	APR 29, 2014	U-323	NCE	MAY 26, 2005
			5679717	APR 29, 2014	U-323		
			5693675	DEC 02, 2014			
			5607669	JUN 10, 2014	U-323		
			5917007	APR 29, 2014	U-323		
			5919832	JUN 10, 2014			
	021176 001	COLESEVELAM HYDROCHLORIDE;WELCHOL	5919832	JUN 10, 2014		NCE	MAY 26, 2005
			5917007	APR 29, 2014	U-323		
			5607669	JUN 10, 2014	U-323		
			5693675	DEC 02, 2014			
			5679717	APR 29, 2014	U-323		
			5624963	APR 29, 2014	U-323		
	020154 002	DIDANOSINE;VIDEX				D-58	OCT 28, 2002
	020154 003	DIDANOSINE;VIDEX				D-58	OCT 28, 2002
	020154 004	DIDANOSINE;VIDEX	5616566	AUG 29, 2006	U-180	D-58	OCT 28, 2002
	020154 005	DIDANOSINE;VIDEX				D-58	OCT 28, 2002
	020154 006	DIDANOSINE;VIDEX				NS	OCT 28, 2002
						D-58	OCT 28, 2002
	020939 001	DILTIAZEM HYDROCHLORIDE;DILTIAZEM HCL	5288505	JUN 26, 2011			
			5529791	JUN 25, 2013			
	020939 002	DILTIAZEM HYDROCHLORIDE;DILTIAZEM HCL	5288505	JUN 26, 2011			
			5529791	JUN 25, 2013			
	020939 003	DILTIAZEM HYDROCHLORIDE;DILTIAZEM HCL	5288505	JUN 26, 2011			
			5529791	JUN 25, 2013			
	020939 004	DILTIAZEM HYDROCHLORIDE;DILTIAZEM HCL	5288505	JUN 26, 2011			
			5529791	JUN 25, 2013			
>ADD>	021168 001	DIVALPROEX SODIUM;DEPAKOTE ER	4988731	JAN 29, 2008		NP	AUG 04, 2003
>ADD>			4913906	APR 03, 2007			
>ADD>	020941 001	DOCOSANOL;ABREVA				NCE	JUL 25, 2005
>ADD>	020623 001	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET	4906775	MAR 06, 2007			
>ADD>	020623 002	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET	4906775	MAR 06, 2007			
>ADD>	020624 001	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET	4906775	MAR 06, 2007			
>ADD>	020869 001	DORZOLAMIDE HYDROCHLORIDE;COSOPT	4797413	APR 28, 2008	U-103		
>ADD>			4619939	OCT 28, 2003	U-104		
	021027 001	DOXERCALCIFEROL;HECTOROL	5602116	APR 03, 2115	U-321	NDF	APR 06, 2003
			5707980	FEB 11, 2117	U-321	NCE	JUN 09, 2004
>ADD>	021145 001	EFLORNITHINE HYDROCHLORIDE;VANIQA	4413141	NOV 01, 2000		NP	JUL 27, 2003
>ADD>			4720489	JAN 19, 2005	U-334		
>ADD>			5648394	JUL 15, 2014	U-334		
	019221 001	ENALAPRIL MALEATE;VASERETIC	4472380	SEP 18, 2001			
			4374829	FEB 22, 2000			
			4374829*PED	AUG 22, 2000			
			4472380*PED	MAR 18, 2002			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	019221 003	ENALAPRIL MALEATE;VASERETIC	4472380	SEP 18, 2001			
			4374829	FEB 22, 2000			
			4374829*PED	AUG 22, 2000			
			4472380*PED	MAR 18, 2002			
	018998 001	ENALAPRIL MALEATE;VASOTEC	4374829	FEB 22, 2000			
			4374829*PED	AUG 22, 2000			
	018998 002	ENALAPRIL MALEATE;VASOTEC	4374829	FEB 22, 2000			
			4374829*PED	AUG 22, 2000			
	018998 003	ENALAPRIL MALEATE;VASOTEC	4374829	FEB 22, 2000			
			4374829*PED	AUG 22, 2000			
	018998 005	ENALAPRIL MALEATE;VASOTEC	4374829	FEB 22, 2000			
			4374829*PED	AUG 22, 2000			
	019309 001	ENALAPRILAT;VASOTEC	4374829	FEB 22, 2000			
			4374829*PED	AUG 22, 2000			
	020444 001	EPOPROSTENOL SODIUM;FLOLAN				ODE	APR 14, 2007
						I-296	APR 14, 2003
	020444 002	EPOPROSTENOL SODIUM;FLOLAN				ODE	APR 14, 2007
						I-296	APR 14, 2003
	020907 001	ESTRADIOL;ACTIVELLE				I-295	APR 11, 2003
	021040 001	ESTRADIOL;ORTHO-PREFEST	5108995	APR 28, 2009	U-311		
			5382573	JAN 17, 2012			
>ADD>	075696 001	ETODOLAC;ETODOLAC				PC	FEB 04, 2001
	020584 001	ETODOLAC;LODINE XL	4966768*PED	APR 30, 2008			
			4966768	OCT 30, 2007			
	020584 002	ETODOLAC;LODINE XL	4966768*PED	APR 30, 2008			
			4966768	OCT 30, 2007			
	020584 003	ETODOLAC;LODINE XL	4966768*PED	APR 30, 2008			
			4966768	OCT 30, 2007			
	019304 002	FENOFIBRATE;TRICOR (MICRONIZED)				I-298	APR 24, 2003
	019304 003	FENOFIBRATE;TRICOR (MICRONIZED)				I-298	APR 24, 2003
	019304 004	FENOFIBRATE;TRICOR (MICRONIZED)				I-298	APR 24, 2003
	020625 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	6037353	MAR 14, 2017	U-138		
	020872 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	5578610	NOV 26, 2013	U-139	NDF	FEB 25, 2003
			5932247	FEB 28, 2015			
			5855912	FEB 28, 2015			
			4254129	FEB 17, 2001	U-139		
			6037353	MAR 14, 2017	U-138		
	020872 002	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	5578610	NOV 26, 2013	U-139	NDF	FEB 25, 2003
			5932247	FEB 28, 2015			
			5855912	FEB 28, 2015			
			4254129	FEB 17, 2001	U-139		
			6037353	MAR 14, 2017	U-138		
	020872 004	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	5578610	NOV 26, 2013	U-139	NDF	FEB 25, 2003
			5932247	FEB 28, 2015			
			5855912	FEB 28, 2015			
			4254129	FEB 17, 2001	U-139		
			6037353	MAR 14, 2017	U-138		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020786 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA-D	6037353	MAR 14, 2017	U-138		
			6039974	JUL 31, 2018			
	019949 004	FLUCONAZOLE;DIFLUCAN	4416682	JUN 02, 2001			
			4404216	JAN 29, 2004			
	020378 001	FOLLITROPIN ALFA/BETA;GONAL-F				ODE	MAY 24, 2007
>ADD>						I-306	MAY 24, 2003
	020378 002	FOLLITROPIN ALFA/BETA;GONAL-F				ODE	MAY 24, 2007
>ADD>						I-306	MAY 24, 2003
	020235 001	GABAPENTIN;NEURONTIN	4087544	JAN 16, 2000	U-86	PED	MAR 29, 2002
			5084479	JAN 02, 2010	U-125	D-43	SEP 29, 2001
			4894476*PED	NOV 02, 2008			
			4087544*PED	JUL 16, 2000	U-86		
			5084479*PED	JUL 02, 2010	U-125		
			4894476	MAY 02, 2008			
			6054482	APR 25, 2017			
			6054482*PED	OCT 25, 2017			
	020235 002	GABAPENTIN;NEURONTIN	4894476	MAY 02, 2008		PED	MAR 29, 2002
			5084479	JAN 02, 2010	U-125	D-43	SEP 29, 2001
			4087544	JAN 16, 2000	U-86		
			5084479*PED	JUL 02, 2010	U-125		
			4894476*PED	NOV 02, 2008			
			4087544*PED	JUL 16, 2000	U-86		
			6054482	APR 25, 2017			
			6054482*PED	OCT 25, 2017			
	020235 003	GABAPENTIN;NEURONTIN	4087544	JAN 16, 2000	U-86	PED	MAR 29, 2002
			5084479	JAN 02, 2010	U-125	D-43	SEP 29, 2001
			4894476	MAY 02, 2008			
			4087544*PED	JUL 16, 2000	U-86		
			5084479*PED	JUL 02, 2010			
			4894476*PED	NOV 02, 2008			
			6054482	APR 25, 2017			
			6054482*PED	OCT 25, 2017			
	020882 001	GABAPENTIN;NEURONTIN	4087544	JAN 16, 2000	U-106		
			4894476	MAY 02, 2008			
			5084479	JAN 02, 2010	U-258		
			5084479*PED	JUL 02, 2010	U-258		
			4087544*PED	JUL 16, 2000	U-106		
			4894476*PED	NOV 02, 2008			
			6054482	APR 25, 2017			
			6054482*PED	OCT 25, 2017			
	020882 002	GABAPENTIN;NEURONTIN	4087544	JAN 16, 2000	U-106		
			4894476	MAY 02, 2008			
			5084479	JAN 02, 2010	U-258		
			4087544*PED	JUL 16, 2000	U-106		
			4894476*PED	NOV 02, 2008			
			5084479*PED	JUL 02, 2010	U-258		
			6054482	APR 25, 2017			
			6054482*PED	OCT 25, 2017			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	021037 001	GADOPENTETATE DIMEGLUMINE;MAGNEVIST	5362475	NOV 08, 2011			
			5560903	OCT 01, 2013			
			4647447	MAR 03, 2004			
			4957939	MAR 03, 2004			
			4963344	MAR 03, 2004			
	020460 002	GANCICLOVIR;CYTOVENE	4507305	MAY 21, 2001	U-64		
			4423050	MAY 21, 2001	U-64		
			4355032	JUN 23, 2003	U-64		
			4642346	JUN 24, 2005			
	021174 001	GEMTUZUMAB OZOGAMICIN;MYLOTARG	5606040	FEB 25, 2014		ODE	MAY 17, 2007
			5693762	DEC 02, 2014		NCE	MAY 17, 2005
			5739116	APR 14, 2015			
			5767285	JUN 16, 2015			
			5773001	JUN 30, 2015	U-320		
			4970198	NOV 30, 2007			
			5079233	JAN 07, 2009			
			5585089	DEC 17, 2013			
	020622 001	GLATIRAMER ACETATE;COPAXONE	5981589	MAY 24, 2014			
			6054430	MAY 24, 2014			
>ADD>	021178 001	GLYBURIDE;GLUCOVANCE				NC	JUL 31, 2003
>ADD>	021178 002	GLYBURIDE;GLUCOVANCE				NC	JUL 31, 2003
>ADD>	021178 003	GLYBURIDE;GLUCOVANCE				NC	JUL 31, 2003
	020125 001	HYDROCHLOROTHIAZIDE;ACCURETIC				NC	DEC 28, 2002
	020125 002	HYDROCHLOROTHIAZIDE;ACCURETIC				NC	DEC 28, 2002
	020125 003	HYDROCHLOROTHIAZIDE;ACCURETIC				NC	DEC 28, 2002
	019778 001	HYDROCHLOROTHIAZIDE;PRINZIDE	4374829	DEC 29, 2001			
	019778 002	HYDROCHLOROTHIAZIDE;PRINZIDE	4374829	DEC 29, 2001			
	019778 003	HYDROCHLOROTHIAZIDE;PRINZIDE	4374829	DEC 29, 2001	U-3		
>ADD>	019771 001	IBUPROFEN;ADVIL COLD AND SINUS	4552899	APR 09, 2004			
>ADD>			4552899*PED	OCT 09, 2004			
>ADD>	019763 003	IFOSFAMIDE;IFEX/MESNEX KIT	5696172	OCT 06, 2013			
			4220660	MAR 06, 2001	U-21		
>ADD>	019763 004	IFOSFAMIDE;IFEX/MESNEX KIT	5696172	OCT 06, 2013			
			4220660	MAR 06, 2001	U-21		
	020986 001	INSULIN ASPART RECOMBINANT;NOVOLOG				NCE	JUN 07, 2005
	021081 001	INSULIN GLARGINE;LANTUS				PED	OCT 20, 2005
						NCE	APR 20, 2005
	020563 001	INSULIN LISPRO;HUMALOG				D-56	APR 04, 2003
	021018 001	INSULIN LISPRO;HUMALOG MIX 50/50				NC	DEC 22, 2002
	020563 002	INSULIN LISPRO;HUMALOG PEN	5474978	JUN 16, 2014		D-56	APR 04, 2003
			5514646	MAY 07, 2013	U-111	NCE	JUN 14, 2001
	020571 001	IRINOTECAN HYDROCHLORIDE;CAMPTOSAR				I-299	APR 20, 2003
>ADD>	020966 001	ITRACONAZOLE;SPORANOX	4727064	FEB 23, 2005			
	019084 001	KETOCONAZOLE;NIZORAL	4942162	FEB 11, 2003			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020857 001	LAMIVUDINE;COMBIVIR	5905082	MAY 18, 2016	U-248		
	020564 001	LAMIVUDINE;EPIVIR	5047407	NOV 17, 2009			
	020596 001	LAMIVUDINE;EPIVIR	5047407	NOV 17, 2009			
	021088 001	LEUPROLIDE ACETATE;VIADUR	5728396	JAN 30, 2017	U-316	NP	MAR 03, 2003
			5932547	JUN 13, 2017			
			5985305	JAN 30, 2017			
	020837 001	LEVALBUTEROL HYDROCHLORIDE;XOPENEX	5362755	NOV 08, 2011	U-332		
			5547994	AUG 20, 2013	U-332		
			5760090	JAN 05, 2010	U-332		
			5844002	JAN 05, 2010	U-332		
	020837 002	LEVALBUTEROL HYDROCHLORIDE;XOPENEX	5362755	NOV 08, 2011	U-332		
			5547994	AUG 20, 2013	U-332		
			5760090	JAN 05, 2010	U-332		
			5844002	JAN 05, 2010	U-332		
	021114 001	LEVOBETAXOLOL HYDROCHLORIDE;BETAXON				NP	FEB 23, 2003
>ADD>	020634 001	LEVOFLOXACIN;LEVAQUIN				I-305	FEB 02, 2003
>ADD>	020634 002	LEVOFLOXACIN;LEVAQUIN				I-305	FEB 02, 2003
>ADD>	020635 001	LEVOFLOXACIN;LEVAQUIN				I-305	FEB 02, 2003
>ADD>	020635 002	LEVOFLOXACIN;LEVAQUIN IN DEXTROSE				I-305	FEB 02, 2003
>ADD>	020635 003	LEVOFLOXACIN;LEVAQUIN IN DEXTROSE				I-305	FEB 02, 2003
	020612 001	LIDOCAINE;LIDODERM				NP	MAR 19, 2002
	021130 001	LINEZOLID;ZYVOX	5688792	NOV 18, 2014	U-319	NCE	APR 18, 2005
	021130 002	LINEZOLID;ZYVOX	5688792	NOV 18, 2014	U-319	NCE	APR 18, 2005
	021131 001	LINEZOLID;ZYVOX	5688792	NOV 18, 2014	U-319	NCE	APR 18, 2005
	021132 001	LINEZOLID;ZYVOX	5688792	NOV 18, 2014	U-319	NCE	APR 18, 2005
	019558 001	LISINOPRIL;PRINIVIL	4374829	DEC 29, 2001			
	019558 002	LISINOPRIL;PRINIVIL	4374829	DEC 29, 2001			
	019558 003	LISINOPRIL;PRINIVIL	4374829	DEC 29, 2001			
	019558 004	LISINOPRIL;PRINIVIL	4374829	DEC 29, 2001			
	019558 006	LISINOPRIL;PRINIVIL	4374829	DEC 29, 2001			
	019777 001	LISINOPRIL;ZESTRIL				I-288	FEB 07, 2003
	019777 002	LISINOPRIL;ZESTRIL				I-288	FEB 07, 2003
	019777 003	LISINOPRIL;ZESTRIL				I-288	FEB 07, 2003
	019777 004	LISINOPRIL;ZESTRIL				I-288	FEB 07, 2003
	019777 005	LISINOPRIL;ZESTRIL				I-288	FEB 07, 2003
	019777 006	LISINOPRIL;ZESTRIL				I-288	FEB 07, 2003
>ADD>	019658 001	LORATADINE;CLARITIN	4282233	JUN 19, 2002	U-77		
>ADD>			4659716	APR 21, 2004	U-142		
>ADD>			4863931	SEP 15, 2008			
>ADD>			4282233*PED	DEC 19, 2002	U-77		
>ADD>			4659716*PED	OCT 21, 2004	U-142		
>ADD>			4863931*PED	MAR 15, 2009			
>ADD>	020641 001	LORATADINE;CLARITIN	4659716	APR 21, 2004	U-142		
>ADD>			4282233	JUN 19, 2002	U-77		
>ADD>			4863931	SEP 15, 2008			
>ADD>			4659716*PED	OCT 21, 2004	U-142		
>ADD>			4863931*PED	MAR 15, 2009			
>ADD>			4282233*PED	DEC 19, 2002	U-77		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXPIRES	EXCL USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020704 001	LORATADINE;CLARITIN REDITABS	4659716	APR 21, 2004	U-142		
>ADD>			4282233	JUN 19, 2002	U-77		
>ADD>			4371516	FEB 01, 2000			
>ADD>			4863931	SEP 15, 2008			
>ADD>			4659716*PED	OCT 21, 2004	U-142		
>ADD>			4282233*PED	DEC 19, 2002	U-77		
>ADD>			4371516*PED	AUG 01, 2000			
>ADD>			4863931*PED	MAR 15, 2009			
>ADD>	019670 001	LORATADINE;CLARITIN-D	4282233	JUN 19, 2002	U-77		
>ADD>			4659716	APR 21, 2004	U-142		
>ADD>			4863931	SEP 15, 2008			
>ADD>			4282233*PED	DEC 19, 2002	U-77		
>ADD>			4659716*PED	OCT 21, 2004	U-142		
>ADD>			4863931*PED	MAR 15, 2009			
>ADD>	020470 001	LORATADINE;CLARITIN-D 24 HOUR	4659716	APR 21, 2004	U-142		
>ADD>			4282233	JUL 19, 2002	U-77		
>ADD>			5314697	OCT 23, 2012			
>ADD>			4863931	SEP 15, 2008			
>ADD>			4659716*PED	OCT 21, 2004	U-142		
>ADD>			4282233*PED	JAN 19, 2003	U-77		
>ADD>			5314697*PED	OCT 23, 2012			
>ADD>			4863931*PED	MAR 15, 2009			
	020938 001	MELOXICAM;MOBIC					
	020049 001	MESALAMINE;PENTASA					
>ADD>	019884 001	MESNA;MESNEX	4980173	JAN 29, 2002	U-78	NCE	APR 13, 2005
	020357 001	METFORMIN HYDROCHLORIDE;GLUCOPHAGE	5696172	OCT 06, 2013			
	020357 002	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				PED	SEP 03, 2000
						NCE	MAR 03, 2000
	020357 005	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				PED	SEP 03, 2000
						NCE	MAR 03, 2000
>ADD>	021121 001	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA				PED	SEP 03, 2000
>ADD>	021121 002	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA				NCE	MAR 03, 2000
	019815 001	MIDODRINE HYDROCHLORIDE;PROAMATINE				NP	AUG 01, 2003
	019815 002	MIDODRINE HYDROCHLORIDE;PROAMATINE				NP	AUG 01, 2003
	020830 002	MONTELUKAST SODIUM;SINGULAIR				ODE	SEP 06, 2003
			5565473	NOV 30, 2010	U-228	ODE	SEP 06, 2003
						I-300	MAR 03, 2003
	020152 001	NEFAZODONE HYDROCHLORIDE;SERZONE				NS	MAR 03, 2003
	020152 002	NEFAZODONE HYDROCHLORIDE;SERZONE	5256664	APR 28, 2012		NCE	FEB 20, 2003
	020152 003	NEFAZODONE HYDROCHLORIDE;SERZONE	5256664	APR 28, 2012			
	020152 004	NEFAZODONE HYDROCHLORIDE;SERZONE	5256664	APR 28, 2012			
	020152 005	NEFAZODONE HYDROCHLORIDE;SERZONE	5256664	APR 28, 2012			
	020152 006	NEFAZODONE HYDROCHLORIDE;SERZONE	5256664	APR 28, 2012			
			5256664	APR 28, 2012			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020381 001	NIACIN;NIASPAN	6080428	MAY 27, 2017	U-331		
020381 002	NIACIN;NIASPAN	6080428	MAY 27, 2017	U-331		
020381 003	NIACIN;NIASPAN	6080428	MAY 27, 2017	U-331		
020381 004	NIACIN;NIASPAN	6080428	MAY 27, 2017	U-331		
020381 005	NIACIN;NIASPAN TITRATION ST	6080428	MAY 27, 2017	U-331		
021134 001	NITROGLYCERIN;NITROSTAT				NDF	MAY 01, 2003
021134 002	NITROGLYCERIN;NITROSTAT				NDF	MAY 01, 2003
021134 003	NITROGLYCERIN;NITROSTAT				NDF	MAY 01, 2003
019921 001	OFLOXACIN;OCUFLOX	4382892	SEP 02, 2003			
		4551456	NOV 14, 2003	U-80		
020592 001	OLANZAPINE;ZYPREXA				I-297	MAR 17, 2003
020592 002	OLANZAPINE;ZYPREXA				I-297	MAR 17, 2003
020592 003	OLANZAPINE;ZYPREXA				I-297	MAR 17, 2003
020592 004	OLANZAPINE;ZYPREXA				I-297	MAR 17, 2003
020592 005	OLANZAPINE;ZYPREXA				I-297	MAR 17, 2003
020592 006	OLANZAPINE;ZYPREXA				I-297	MAR 17, 2003
021086 001	OLANZAPINE;ZYPREXA ZYDIS	5457895	SEP 30, 2013		NCE	SEP 30, 2001
		5229382	APR 23, 2011	U-324		
		5605897	FEB 25, 2014	U-325		
		5627178	APR 23, 2011	U-326		
		5736541	MAR 24, 2015	U-328		
		5817655	APR 23, 2011	U-327		
		5817656	APR 23, 2011	U-326		
021086 002	OLANZAPINE;ZYPREXA ZYDIS	5457895	SEP 30, 2013		NCE	SEP 30, 2001
		5229382	APR 23, 2011	U-324		
		5605897	FEB 25, 2014	U-325		
		5627178	APR 23, 2011	U-326		
		5736541	MAR 24, 2015	U-328		
		5817655	APR 23, 2011	U-327		
		5817656	APR 23, 2011	U-326		
021086 003	OLANZAPINE;ZYPREXA ZYDIS	5457895	SEP 30, 2013		NCE	SEP 30, 2001
		5736541	MAR 24, 2015	U-328		
		5817655	APR 23, 2011	U-327		
		5817656	APR 23, 2011	U-326		
		5229382	APR 23, 2011	U-324		
		5605897	FEB 25, 2014	U-325		
		5627178	APR 23, 2011	U-326		
021086 004	OLANZAPINE;ZYPREXA ZYDIS	5457895	SEP 30, 2013		NCE	SEP 30, 2001
		5229382	APR 23, 2011	U-324		
		5605897	FEB 25, 2014	U-325		
		5627178	APR 23, 2011	U-326		
		5736541	MAR 24, 2015	U-328		
		5817655	APR 23, 2011	U-327		
		5817656	APR 23, 2011	U-326		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020688 001	OLOPATADINE HYDROCHLORIDE;PATANOL				I-301	MAR 20, 2003
	019715 001	OLSALAZINE SODIUM;DIPENTUM	4559330	JUL 31, 2004	U-58		
>ADD>	020103 001	ONDANSETRON HYDROCHLORIDE;ZOFRAN	5344658	SEP 06, 2011			
>ADD>	020103 002	ONDANSETRON HYDROCHLORIDE;ZOFRAN	5344658	SEP 06, 2011			
>ADD>	020103 003	ONDANSETRON HYDROCHLORIDE;ZOFRAN	5344658	SEP 06, 2011		I-269	AUG 27, 2002
>ADD>			5578628	JUN 24, 2006	U-44		
>ADD>			4753789	JUN 24, 2006	U-44		
>ADD>			4695578	JAN 25, 2005			
>ADD>	020605 001	ONDANSETRON HYDROCHLORIDE;ZOFRAN	4695578	JAN 25, 2005	U-183		
>ADD>	020781 001	ONDANSETRON;ZOFRAN ODT	4695578	JAN 25, 2005	U-330		
			5955488	NOV 14, 2015			
			6063802	NOV 14, 2015			
			4753789	JUN 24, 2006	U-329		
			5578628	JUN 24, 2006	U-330		
>ADD>	020781 002	ONDANSETRON;ZOFRAN ODT	4695578	JAN 25, 2005	U-330		
			5955488	NOV 14, 2015			
			6063802	NOV 14, 2015			
			4753789	JUN 24, 2006	U-330		
			5578628	JUN 24, 2006	U-330		
	020766 001	ORLISTAT;XENICAL	6004996	JAN 06, 2018			
	021014 001	OXCARBAZEPINE;TRILEPTAL				NCE	JAN 14, 2005
	021014 002	OXCARBAZEPINE;TRILEPTAL				NCE	JAN 14, 2005
	021014 003	OXCARBAZEPINE;TRILEPTAL				NCE	JAN 14, 2005
>ADD>	020262 001	PACLITAXEL;TAXOL	6096331	FEB 22, 2013		D-57	JUN 20, 2003
	020987 001	PANTOPRAZOLE SODIUM;PROTONIX	4758579	JUL 19, 2005		NCE	FEB 02, 2005
	020819 001	PARICALCITOL;ZEMPLAR	5246925	SEP 21, 2010	U-314		
			5587497	DEC 24, 2013			
	020031 001	PAROXETINE HYDROCHLORIDE;PAXIL	6063927	APR 23, 2019			
			6080759	MAY 19, 2015			
	020031 002	PAROXETINE HYDROCHLORIDE;PAXIL	6063927	APR 23, 2019			
			6080759	MAY 19, 2015			
	020031 003	PAROXETINE HYDROCHLORIDE;PAXIL	6063927	APR 23, 2019			
			6080759	MAY 19, 2015			
	020031 004	PAROXETINE HYDROCHLORIDE;PAXIL	6063927	APR 23, 2019			
			6080759	MAY 19, 2015			
	020031 005	PAROXETINE HYDROCHLORIDE;PAXIL	6063927	APR 23, 2019			
			6080759	MAY 19, 2015			
	020710 001	PAROXETINE HYDROCHLORIDE;PAXIL	6063927	APR 23, 2019			
			6080759	MAY 19, 2015			
	020885 001	PAROXETINE HYDROCHLORIDE;PAXIL	6063927	APR 23, 2019			
			6080759	MAY 19, 2015			
	020885 002	PAROXETINE HYDROCHLORIDE;PAXIL	6063927	APR 23, 2019			
			6080759	MAY 19, 2015			
	020885 003	PAROXETINE HYDROCHLORIDE;PAXIL	6063927	APR 23, 2019			
			6080759	MAY 19, 2015			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020885 004	PAROXETINE HYDROCHLORIDE;PAXIL	6062927	APR 23, 2019			
		6080759	MAY 19, 2015			
020936 001	PAROXETINE HYDROCHLORIDE;PAXIL CR	6063927	APR 23, 2019			
		6080759	MAY 19, 2015			
020936 002	PAROXETINE HYDROCHLORIDE;PAXIL CR	6063927	APR 23, 2019			
		6080759	MAY 19, 2015			
021084 001	PERFLUOROPOLYMETHYLISOPROPYL ETHER;SKIN EXPOSURE REDUCT	5607979	MAY 30, 2015		NCE	FEB 17, 2005
019898 002	PRAVASTATIN SODIUM;PRAVACHOL				I-281	JUN 09, 2003
					I-304	JAN 18, 2003
					I-287	FEB 10, 2003
					I-286	JAN 18, 2003
					D-51	JAN 18, 2003
019898 003	PRAVASTATIN SODIUM;PRAVACHOL				I-281	JUN 09, 2003
					I-304	JAN 18, 2003
					I-287	FEB 10, 2003
					I-286	JAN 18, 2003
					D-51	JAN 18, 2003
019898 004	PRAVASTATIN SODIUM;PRAVACHOL				I-281	JUN 09, 2003
					I-304	JAN 18, 2003
					I-287	FEB 10, 2003
					I-286	JAN 18, 2003
					D-51	JAN 18, 2003
019157 001	PREDNISOLONE SODIUM PHOSPHATE;PEDIAPRED	4448774	DEC 22, 2002			
020630 001	REMIFENTANIL HYDROCHLORIDE;ULTIVA	5019583*PED	AUG 15, 2009		NPP	OCT 15, 2002
		5466700	AUG 30, 2013	U-156	PED	APR 15, 2003
		5019583	FEB 15, 2009		PED	JAN 12, 2002
		5466700*PED	MAR 01, 2014	U-156	NCE	JUL 12, 2001
020630 002	REMIFENTANIL HYDROCHLORIDE;ULTIVA	5019583	FEB 15, 2009		NPP	OCT 15, 2002
		5466700	AUG 30, 2013	U-156	PED	APR 15, 2003
		5019583*PED	AUG 15, 2009		PED	JAN 12, 2002
		5466700*PED	MAR 01, 2014		NCE	JUL 12, 2001
020630 003	REMIFENTANIL HYDROCHLORIDE;ULTIVA	5019583	FEB 15, 2009		NPP	OCT 15, 2002
		5466700	AUG 30, 2013	U-156	PED	APR 15, 2003
		5019583*PED	AUG 15, 2009		PED	JAN 12, 2002
		5466700*PED	MAR 01, 2014	U-156	NCE	JUL 12, 2001
020903 001	RIBAVIRIN;REBETOL	6051252	DEC 22, 2017			
020835 001	RISEDRONATE SODIUM;ACTONEL				I-292	APR 14, 2003
					I-291	APR 14, 2003
					I-290	APR 14, 2003
					I-293	APR 14, 2003
020588 001	RISPERIDONE;RISPERDAL	5453425	JUL 11, 2014			
		5616587	JUL 11, 2014			
020659 001	RITONAVIR;NORVIR	6037157	JUN 26, 2016			
		5674882	OCT 07, 2014			
		5886036	DEC 29, 2012			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020823 003	RIVASTIGMINE TARTRATE;EXELON	4948807	AUG 14, 2007	U-322	NCE	APR 21, 2005
			5602176	FEB 11, 2014	U-322		
	020823 004	RIVASTIGMINE TARTRATE;EXELON	4948807	AUG 14, 2007	U-322	NCE	APR 21, 2005
			5602176	FEB 11, 2014	U-322		
	020823 005	RIVASTIGMINE TARTRATE;EXELON	4948807	AUG 14, 2007	U-322	NCE	APR 21, 2005
			5602176	FEB 11, 2014	U-322		
	020823 006	RIVASTIGMINE TARTRATE;EXELON	4948807	AUG 14, 2007	U-322	NCE	APR 21, 2005
			5602176	FEB 11, 2014	U-322		
	021025 001	RIVASTIGMINE TARTRATE;EXELON	4948807	AUG 14, 2007	U-322	NCE	APR 21, 2005
			5602176	FEB 11, 2014	U-322		
	020864 001	RIZATRIPTAN BENZOATE;MAXALT	5602162	FEB 11, 2014			
	020864 002	RIZATRIPTAN BENZOATE;MAXALT	5602162	FEB 11, 2014			
	021042 001	ROFECOXIB;VIOXX	6063811	MAY 16, 2017	U-266		
	021042 002	ROFECOXIB;VIOXX	6063811	MAY 16, 2017	U-266		
	021052 001	ROFECOXIB;VIOXX	6063811	MAY 16, 2017	U-266		
	021052 002	ROFECOXIB;VIOXX	6063811	MAY 16, 2017	U-266		
	021071 002	ROSIGLITAZONE MALEATE;AVANDIA	5002953	AUG 30, 2008	U-329	I-289	APR 03, 2003
			5741803	APR 21, 2015	U-329		
	021071 003	ROSIGLITAZONE MALEATE;AVANDIA	5002953	AUG 30, 2008	U-329	I-289	APR 03, 2003
			5741803	APR 21, 2015	U-329		
	021071 004	ROSIGLITAZONE MALEATE;AVANDIA	5002953	AUG 30, 2008	U-329	I-289	APR 03, 2003
			5741803	APR 21, 2015	U-329		
	020990 001	SERTRALINE HYDROCHLORIDE;ZOLOFT	4536518	DEC 30, 2005	U-286		
			4940731	AUG 30, 2009	U-312		
	021179 001	SEVELAMER HYDROCHLORIDE;RENAGEL	5496545	AUG 11, 2013	U-246	NCE	OCT 30, 2003
			5667775	SEP 16, 2014	U-246		
	021179 002	SEVELAMER HYDROCHLORIDE;RENAGEL	5496545	AUG 11, 2013	U-246	NCE	OCT 30, 2003
			5667775	SEP 16, 2014	U-246		
>ADD>	020478 001	SEVOFLURANE;ULTANE	5990176	JAN 27, 2017		NCE	JUN 07, 2000
>ADD>			6074668	JAN 09, 2018		PED	DEC 07, 2000
>ADD>			5990176*PED	JUL 27, 2017			
>ADD>			6074668*PED	JUL 09, 2018			
	020280 006	SOMATROPIN RECOMBINANT;GENOTROPIN				I-302	JUN 20, 2003
>ADD>						ODE	JUN 20, 2007
	020280 007	SOMATROPIN RECOMBINANT;GENOTROPIN				I-302	JUN 20, 2003
>ADD>						ODE	JUN 20, 2007
	020280 001	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5435076	APR 16, 2013		I-302	JUN 20, 2003
>ADD>			5716338	FEB 10, 2015		ODE	JUN 20, 2007
	020280 002	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5435076	APR 16, 2013		I-302	JUN 20, 2003
>ADD>			5716338	FEB 10, 2015		ODE	JUN 20, 2007
	020280 003	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5435076	APR 16, 2013		I-302	JUN 20, 2003
>ADD>			5716338	FEB 10, 2015		ODE	JUN 20, 2007
	020280 004	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT				I-302	JUN 20, 2000
>ADD>						ODE	JUN 20, 2007

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020280 005	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5435076	APR 16, 2013		I-302	JUN 20, 2003
>ADD>			5716338	FEB 10, 2015		ODE	JUN 20, 2007
	020280 008	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5435076	APR 16, 2013		I-302	JUN 20, 2003
>ADD>			5716338	FEB 10, 2015		ODE	JUN 20, 2007
	020280 009	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5435076	APR 16, 2013		I-302	JUN 20, 2003
>ADD>			5716338	FEB 10, 2015		ODE	JUN 20, 2007
	020280 010	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5435076	APR 16, 2013		I-302	JUN 20, 2003
>ADD>			5716338	FEB 10, 2015		ODE	JUN 20, 2007
	020280 011	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5716338	FEB 10, 2015		I-302	JUN 20, 2003
>ADD>			5435076	APR 16, 2013		ODE	JUN 20, 2007
	020280 012	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5435076	APR 16, 2013		I-302	JUN 20, 2003
>ADD>			5716338	FEB 10, 2015		ODE	JUN 20, 2007
	020280 013	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5435076	APR 16, 2013		I-302	JUN 20, 2003
>ADD>			5716338	FEB 10, 2015		ODE	JUN 20, 2007
	019721 001	SOMATROPIN RECOMBINANT;NORDITROPIN	5633352	MAY 27, 2014			
	019721 002	SOMATROPIN RECOMBINANT;NORDITROPIN	5633352	MAY 27, 2014			
	019676 001	SOMATROPIN RECOMBINANT;NUTROPIN				D-55	APR 13, 2003
						M-2	DEC 01, 2002
	019676 002	SOMATROPIN RECOMBINANT;NUTROPIN				D-55	APR 13, 2003
						M-2	DEC 01, 2002
	020522 001	SOMATROPIN RECOMBINANT;NUTROPIN AQ				D-55	APR 13, 2003
						M-2	DEC 01, 2002
	021151 001	SOTALOL HYDROCHLORIDE;BETAPACE AF				NP	FEB 22, 2003
	021151 002	SOTALOL HYDROCHLORIDE;BETAPACE AF				NP	FEB 22, 2003
	021151 003	SOTALOL HYDROCHLORIDE;BETAPACE AF				NP	FEB 22, 2003
	021124 001	TERBINAFINE HYDROCHLORIDE;LAMISIL AT	4680291	JUL 14, 2004	U-73		
			4755534	DEC 30, 2006	U-73		
			5681849	OCT 28, 2014			
	021015 001	TESTOSTERONE;ANDROGEL				NDF	FEB 28, 2003
>ADD>	020484 001	TINZAPARIN SODIUM;INNOHEP				NCE	JUL 14, 2005
	020771 001	TOLTERODINE TARTRATE;DETROL	5559269	MAY 05, 2015	U-318		
	020771 002	TOLTERODINE TARTRATE;DETROL	5559269	MAY 05, 2015	U-318		
	020281 001	TRAMADOL HYDROCHLORIDE;ULTRAM				PED	SEP 03, 2000
						PED	FEB 21, 2002
						NCE	MAR 03, 2000
						D-44	AUG 21, 2001
	020281 002	TRAMADOL HYDROCHLORIDE;ULTRAM				PED	FEB 21, 2002
						PED	SEP 03, 2000
						NCE	MAR 03, 2000
						D-44	AUG 21, 2001
	074973 001	TRIMETHOPRIM HYDROCHLORIDE;PRIMSOL	5763449	AUG 07, 2016			
			5962461	AUG 07, 2016			
	020326 001	TRIMETREXATE GLUCURONATE;NEUTREXIN	6017922	MAY 18, 2018			
	020326 002	TRIMETREXATE GLUCURONATE;NEUTREXIN	6017922	MAY 18, 2018			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020715 001	TRIPTORELIN PAMOATE;TRELSTAR DEPOT	5134122	JUL 20, 2010		NCE	JUN 15, 2005
>ADD>			5225205	JUL 20, 2010			
>ADD>			5192741	MAR 09, 2010			
	020719 001	TROGLITAZONE;PRELAY	6046202	SEP 15, 2013	U-317		
	020719 002	TROGLITAZONE;PRELAY	6046202	SEP 15, 2013	U-317		
	020719 003	TROGLITAZONE;PRELAY	6046202	SEP 15, 2013	U-317		
	020720 001	TROGLITAZONE;REZULIN	6046202	SEP 15, 2013	U-317		
	020720 002	TROGLITAZONE;REZULIN	6046202	SEP 15, 2013	U-317		
	020720 003	TROGLITAZONE;REZULIN	6046202	SEP 15, 2013	U-317		
	020552 001	VERAPAMIL HYDROCHLORIDE;COVERA-HS	5232705	AUG 31, 2010			
			5200196	JAN 22, 2008			
			5141752	JUN 27, 2006			
			5082668	JAN 21, 2009			
			5030456	NOV 07, 2008			
			4946687	OCT 02, 2007			
			5785994	OCT 22, 2009	U-315		
	020552 002	VERAPAMIL HYDROCHLORIDE;COVERA-HS	5232705	AUG 31, 2010			
			5200196	JAN 22, 2008			
			5141752	JUN 27, 2006			
			5082668	JAN 21, 2009			
			5030456	NOV 07, 2008			
			4946687	OCT 02, 2007			
			5785994	OCT 22, 2009	U-315		
	021119 001	VERTEPORFIN;VISUDYNE				NCE	APR 12, 2005
	021036 001	ZANAMIVIR;RELENZA				I-294	APR 26, 2003
	020789 001	ZONISAMIDE;ZONEGRAN				NCE	MAR 27, 2005

PATENT AND EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE PATENT AND EXCLUSIVITY COLUMNS, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 20TH EDITION FOR A FULL LISTING OF PATENT AND EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). THE CUMULATIVE SUPPLEMENT WILL LIST NEW CODES ADDED SINCE THE LAST ANNUAL EDITION.

ABBREVIATIONS

NPP	**NEW PATIENT POPULATION**

REFERENCES

NEW DOSING SCHEDULE

D-51	**OPTIONAL STARTING DOSE OF 40MG/DAY**
D-52	**ALTERNATE DOSING REGIMEN OF 1250MG TWICE DAILY**
D-53	**USE IN PEDIATRIC PATIENTS FROM 1 MONTH TO 16 YEARS OF AGE**
D-54	**USE OF ZYBAN FOR MAINTENANCE THERAPY. TREATMENT UP TO 6 MONTHS WAS SHOWN EFFICACIOUS**
D-55	**ADDITION OF A HIGHER DOSE OF NUTROPIN FOR PUBERTAL PATIENTS (PUBERTAL DOSE LESS THAN OR EQUAL TO 0.7MG/KG/WEEK)**
D-56	**ADDITION OF POSTPRANDIAL DOSING**
D-57	**3-HOUR INFUSION OF TAXOL GIVEN EVERY THREE WEEKS AT A DOSE OF 175MG/M2 FOLLOWED BY CISPLATIN AT A DOSE OF 75MG/M2 FOR THE FIRST-LINE TREATMENT OF ADVANCED OVARIAN CANCER**
D-58	**CHANGE IN DOSING INTERVAL TO ONCE-DAILY ADMINISTRATION**
D-59	**REDUCTION OF ELEVATED LDL-C IN A NEW, HIGHER STRENGTH TABLET, 0.8MG, AND FOR EXTENSION OF THE DOSAGE RANGE TO 0.8MG DAILY**

NEW INDICATION

I-283	**TO REDUCE THE INCIDENCE OF MODERATE TO SEVERE XEROSTOMIA IN PATIENTS UNDERGOING POST-OPERATIVE RADIATION TREATMENT FOR HEAD AND NECK CANCER, WHERE THE RADIATION PORT INCLUDES A SUBSTANTIAL PORTION OF THE PAROTID GLANDS**
I-286	**TREATMENT OF PATIENTS WITH FREDERICKSON TYPE III**
I-287	**USE OF PRAVASTATIN IN PATIENTS WITH EVIDENT CORONARY HEART DISEASE TO REDUCE THE RISK OF TOTAL MORTALITY BY REDUCING CORONARY DEATH**
I-288	**CHANGES SEVERAL SECTIONS OF THE PACKAGE INSERT TO INCORPORATE STATEMENTS CONCERNING THE USE OF HIGH DOSES OF LISINOPRIL TO REDUCE THE RISK OF THE COMBINED OUTCOMES OF MORTALITY AND HOSPITALIZATION IN PATIENTS WITH CONGESTIVE HEART FAILURE**
I-289	**USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES MELLLITUS WHEN DIET AND EXERCISE WITH EITHER SINGLE AGENT DOES NOT ACHIEVE ADEQUATE GLYCEMIC CONTROL**
I-290	**TREATMENT OF CORTICOSTEOID-INDUCED OSTEOPOROSIS**
I-291	**PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS**
I-292	**TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS**
I-293	**TREATMENT OF CORTICOSTEROID-INDUCED OSTEOPOROSIS**

PATENT AND EXCLUSIVITY TERMS

NEW INDICATION

I-294	TREATMENT OF UNCOMPLICATED ACUTE ILLNESS DUE TO INFLUENZA A AND B IN PEDIATRIC PATIENTS 7 YEARS AND OLDER WHO HAVE BEEN SYMPTOMATIC FOR NO MORE THAN 2 DAYS	U-321
I-295	PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR WOMEN WITH AN INTACT UTERUS	U-322
I-296	LONG-TERM INTRAVENOUS TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH THE SCLERODERMA SPECTRUM OF DISEASE IN NYHA CLASS III AND CLASS IV PATIENTS WHO DO NOT RESPOND TO CONVENTIONAL THERAPY	U-323 U-324
I-297	SHORT-TERM TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER	
I-298	TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IIA AND IIB HYPERLIPOPROTEINEMIA	U-325
I-299	USE OF CAMPTOSAR AS A COMPONENT OF FIRST-LINE THERAPY IN COMBINATION WITH 5-FLUROURACIL AND LEUCOVARIN FOR PATIENTS WITH METASTATIC CARCINOMA OF THE COLON OR RECTUM	U-326 U-327
I-300	PROPHYLAXIS FOR ASTHMA IN CHILDREN 2-5 YEARS OF AGE	
I-301	TREATMENT OF SIGNS AND SYMPTOMS OF ALLERGIC CONJUNCTIVITIS	U-328
I-302	TREATMENT OF PEDIATRIC PATIENTS WITH PRADER-WILLI SYNDROME	U-329
I-303	INCREASING HDL-CHOLESTEROL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIAS	
I-304	TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IV	U-330
I-305	TREATMENT OF LEVOFLOXACIN SUSCEPTIBLE STRAINS OF PENICILLIN-RESISTANT STREPTOCOCCUS PNEUMONIAE IN PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA	U-331 U-332
I-306	INDUCTION OF SPERMATOGENESIS IN MEN WITH PRIMARY AND SECONDARY HYPOGONADOTROPIC HYPOGONADISM IN WHOM THE CAUSE OF INFERTILITY IS NOT DUE TO PRIMARY TESTICULAR FAILURE	U-333 U-334

MISCELLANEOUS EXCLUSIVITY CODES

M-2	APPROVAL FOR ADDTION TO CLINICAL PHARMACOLOGY SECTION OF THE LABEL REGARDING (1) IMPROVEMENT IN BONE MINERAL DENSITY IN CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENT PATIENTS AND (2) INCREASES IN SERUM ALKALINE PHOSPHATASE
M-3	ADDITION OF EFFICACY AND SAFETY INFORMATION IN WHICH FOSAMAX WAS USED CONCOMITANTLY WITH ESTROGEN ALONE OR WITH ESTROGEN PLUS PROGESTIN

PATENT USE CODE

U-266	RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS; MANAGEMENT OF ACUTE PAIN IN ADULTS; TREATMENT OF PRIMARY DYSMENORRHEA
U-309	TREATING SJOEGREN SYNDROME
U-310	TREATMENT OF XEROSTOMIA
U-311	HORMONE REPLACEMENT
U-312	PANIC DISORDER OBSESSIVE-COMPULSIVE DISORDER POSTTRAUMATIC STRESS DISORDER
U-313	TREATMENT OF CONGESTIVE HEART FAILURE
U-314	METHOD FOR TREATING HYPERPARATHYROIDISM WHICH COMPRISES SUPPRESSING PARATHYROID ACTIVITY
U-315	METHOD FOR ADMINISTERING DRUG TO GASTROINTESTINAL TRACT
U-316	METHOD OF TREATING A SUBJECT SUFFERING FROM PROSTATE CANCER
U-317	METHOD OF USING TROGLITAZONE TO TREAT PATIENTS HAVING INSULIN RESISTANCE
U-318	TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE
U-319	TREATMENT OF MICROBIAL INFECTIONS
U-320	INHIBITING OR ELIMINATING ACUTE MYELOID LEUKEMIA

PATENT AND EXCLUSIVITY TERMS

PATENT USE CODE

REDUCTION OF ELEVATED IPTH LEVELS IN THE MGT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS UNDERGONG CHRONIC RENAL DIALYSIS

TREATMENT OF ALZHEIMER'S DEMENTIA

USE AS A BILE ACID SEQUESTRANT

METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN, SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS OR ACUTE MANIA EMPLOYING OLANZAPINE

METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS, INCLUDING "BIPOLAR DISORDER NOS" EMPLOYING OLANZAPINE

METHOD OF TREATING SCHIZOPHRENIA AND BIPOLAR DISORDER

METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED PSYCHOTIC CONDITIONS EMPLOYING OLANZAPINE

METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS INCLUDING "A PSYCHOTIC CONDITION" EMPLOYING AN OLANZAPINE POLYMORPH

USE OF AVANDIA AS MONOTHERAPY, IN COMBINATION WITH METFORMIN, AND IN

COMBINATION WITH SULFONYLUREAS TO IMPROVE GLYCEMIC CONTROL IN PATIENTS

WITH TYPE 2 DIABETES MELLITUS

TREATMENT OF NAUSEA AND VOMITING

METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER

DAY IN THE EVENING OR AT NIGHT

TREATMENT OR PREVENTION OF BRONCHOSPASM

METHOD OF TREATING OCULAR HYPERTENSION

TREATMENT OF EXCESSIVE FEMALE FACIAL HAIR

*U.S. Government Printing Office: 2000 — 460-922/21001